Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-C]quinolin-2-one compounds having blood-brain barrier penetration ability
By developing 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinoline-2-one derivatives that can penetrate the blood-brain barrier, the problem that existing treatments cannot effectively treat brain cancer has been solved, achieving effective inhibition and radiosensitization effects against brain cancer.
Patent Information
- Application Number
- CN202080103356.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-09-21
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-09-21
AI Technical Summary
Existing treatment methods are unable to effectively penetrate the blood-brain barrier and cannot achieve an effective amount of ATM inhibitors in the brain, resulting in limited therapeutic effects on brain cancers such as glioblastoma and DIPG.
To develop 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinoline-2-one derivatives with the ability to penetrate the blood-brain barrier, as ATM protein kinase inhibitors, for use in combination with radiotherapy or DNA double-strand breakers to improve the efficacy of brain cancer treatment.
These compounds can penetrate the blood-brain barrier, provide effective ATM inhibition, enhance the effects of radiotherapy, reduce efflux rates and the risk of drug interactions, and improve the treatment efficacy for brain cancer.
Smart Images

Figure CN116056698B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to novel 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinolin-2-one derivatives, salts, hydrates and polymorphs thereof, and in particular to substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinolin-2-one compounds having the ability to penetrate the blood-brain barrier and selectively regulate ataxia telangiectasia mutated (ATM) kinase. The present invention also relates to the use of such compounds and their salts for treating or preventing ATM kinase-mediated diseases (including cancer), in particular when used in combination with radiotherapy or with a DNA double-strand break agent for gliomas, glioblastomas, diffuse intrinsic pontine gliomas and cancers with central nervous system metastases. Background Art
[0002] ATM (ataxia-telangiectasia mutation) kinase is a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family of serine / threonine protein kinases located on human chromosome 11 (11q22.3), consisting of 69 exons distributed on 150kb genomic DNA, including DNA-dependent protein kinase catalytic subunit (DNA-PKcs / PRKDC), mammalian rapamycin target protein (MTOR / FRAP) and genital morphogenesis inhibitor (SMG1). The cellular functions of ATM kinase range from the regulation of DNA damage response (DDR) to cell survival, proliferation, metabolism, differentiation, movement and unmediated mRNA degradation (SP Jackson, J. Bartek, Nature, Vol. 461 (2010), pp. 1071-1078, A. Ciccia, SJ Elledge Mol Cell, Vol. 40 (2011), pp. 179-204).
[0003] ATM kinase plays a crucial role in the activation of the G1 / S cell cycle checkpoint, preventing cells with damaged DNA from entering the S phase. ATM-deficient cells are sensitive to DNA double-strand break inducers such as ionizing radiation and topoisomerase-II inhibitors (doxorubicin, etoposide, etoposide, teniposide, doxorubicin, idarubicin, epirubicin and mitoxantrone) and agents that convert single-strand breaks to double-strand breaks during replication such as topoisomerase-I inhibitors (irinotecan and topotecan, etc.), making ATM an attractive target for anticancer chemotherapy sensitization and radiosensitization, so ATM kinase inhibitors are expected to be used as a rational combination product of existing therapies for the treatment of cancer.
[0004] ATM forms homodimers or higher multimers in its inactive state, which dissociate into active monomers after rapid intermolecular autophosphorylation of serine 1981, which is a direct pharmacodynamic and patient selection biomarker for tumor pathways dependent on ATM activation. The recruitment of ATM to DNA double-strand breaks (DSB) sites is mediated by the MRE11-RAD50-NBS1 (MRN) complex. The MRN complex is rapidly assembled at the site of DNA DSB, where it acts as a damage sensor, and the complex can also form a physical bridge across the DSB (THStracker, JHJPetrini, Nat Rev Mol Cell Biol, Vol. 12 (2011), pp. 90-103).
[0005] ATM recruitment has been shown to require binding of ATM to the C-terminus of NBS1, and this interaction also enhances the kinase activity of ATM (Z. You, C. Chahwan, J. Bailis, T. Hunter, P. Russell, Mol Cell Biol, Vol. 25 (2005), pp. 5363-5379). After recruitment to the DNA DSB site, ATM immediately participates in the phosphorylation of the histone variant H2AX on serine 139 (S. Burma, BP Chen, M. Murphy, A. Kurimasa, DJ Chen, Biol Chem, Vol. 276 (2001), pp. 42462-42467), which triggers a cascade reaction for the assembly of DDR components at the break site (TT Paull, EP Progakou, V. Yamazaki, CU Kirchgessner, M. Gellert, WM Bonner, Curr Biol, Vol. 10 (2000), pp. 886-895).
[0006] Downstream targets of ATM include the tumor suppressor protein p53 and the G1 / S cell cycle checkpoint kinase 2 (CHK2). ATM also contributes to the activation of the intra-S phase checkpoint, as ATM-deficient cells do not reduce DNA synthesis after the induction of DNA DSBs, a phenotype known as radioresistant DNA synthesis. The S phase checkpoint function of ATM in response to ionizing radiation (IR) is mediated in part through phosphorylation of NBS1 and SMC1. Additional reinforcement of the intra-S phase checkpoint by ATM is mediated through its activation of CHK2, which induces ubiquitination and degradation of the S phase-promoting phosphatase Cdc25A, which promotes S phase progression by activating cyclin-dependent kinase 2 (Cdk2), which is required for DNA synthesis. In response to IR, hundreds of substrates are phosphorylated in an ATM-dependent manner, and ATM plays a role in the regulation of signaling pathways involved in the maintenance of cellular homeostasis through DDR-independent actions, including cellular metabolism, responses to hypoxia, and oxidative stress.
[0007] Glioblastoma or glioblastoma multiforme (GBM) is an advanced malignant WHO grade IV brain tumor. Due to the presence of the blood-brain barrier (BBB), there is currently no targeted therapy that can reach an effective amount in the brain approved for the treatment of GBM or DIPG patients. Radiotherapy and surgery combined with temozolomide are still the main treatments, but the therapeutic effect is limited. Especially for DIPG patients, radiation is the only treatment option and will relapse within 5.5 months. See, for example, Hamer et al., Neuro-Oncology, Vol. 12, No. 3: pp. 304-316, 2010. GBM is a whole brain disease, and all GBMs have clinically significant tumor areas and have intact BBB. Failure to provide effective treatment to all areas of GBM will lead to treatment failure, and recurrence is inevitable (Sarkaria et al., Neuro-Oncology, Vol. 20, No. 2: pp. 184-191, 2018). The role of ATM in radiosensitivity and the potential use of blood-brain barrier-penetrating ATM inhibitors as radiosensitizers may be very useful in the treatment of brain cancer or cancer with CNS metastases, especially for indications such as DIPG where radiation is the only therapeutic option. Summary of the invention
[0008] In view of the importance of radioresistance in the above-mentioned brain cancers (especially glioblastoma, DIPG and cancers with central nervous system metastases), ATM inhibitors that can penetrate the blood-brain barrier and reach an effective amount in the cranium are particularly useful for treating or preventing cancer. The object of the present invention is to provide substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinolin-2-one compounds having the desired ability to penetrate the blood-brain barrier and the pharmaceutical characteristics of ATM protein kinase inhibitors and their uses.
[0009] The present invention shows a number of compounds with favorable physical and chemical properties (e.g., high permeability and low efflux rate) and / or favorable toxicity characteristics (e.g., reduction of hERG and low drug-drug interaction tendency) and / or other more favorable metabolic profiles (non-aldehyde oxidase substrates). Therefore, when combined with radiation therapy or other DNA double-strand break agents, such compounds have an effective amount in the brain by penetrating the blood-brain barrier for the treatment and / or prevention of central nervous system metastases and brain cancer.
[0010] The purpose of the present invention is achieved through the following technical solutions:
[0011] The present invention relates to compounds comprising the structures of formula (I), (II) and (III), wherein the compounds are:
[0012]
[0013]
[0014] wherein R1 is independently selected from OC1-3 alkyl, OC3-5 cycloalkyl, OC1-C3 deuterated alkyl, dialkylamine, substituted C4-C6 cyclic amine or diazabicyclic amine;
[0015] R2 is independently selected from hydrogen or fluorine;
[0016] R3 is independently selected from methyl or deuterated methyl;
[0017] R4 is independently selected from C1-C3 alkyl or C1-C3 deuterated alkyl.
[0018] Preferably, in formula (I), (II) and (III)
[0019] R1 is independently selected from methoxy, ethoxy, isopropoxy, cyclopropyloxy, deuterated methoxy, dimethylamine, N,N-dimethylazetidin-3-amine or 2-methyl-2,6-diazabicyclo[3.2.0]heptane;
[0020] R2 is independently selected from hydrogen or fluorine;
[0021] R3 is independently selected from methyl or deuterated methyl;
[0022] R4 is independently selected from methyl, ethyl, isopropyl or deuterated methyl.
[0023] The present invention also relates to a pharmaceutical composition comprising the aforementioned compound, its salt, its solvate, its hydrate or its polymorph, and a pharmaceutically acceptable excipient or auxiliary component.
[0024] The present invention also relates to an ATM inhibitor, which is the active ingredient of the above compound; the inhibitor can penetrate the blood-brain barrier.
[0025] The present invention also relates to the use of the aforementioned compound or the aforementioned pharmaceutical composition or the aforementioned inhibitor in the preparation of a drug for treating or preventing a disease mediated by ATM kinase.
[0026] Preferably, the protein is a kinase having activated ATM.
[0027] Preferably, the disease is a CNS metastatic disease of cancer, a proliferative disease, brain cancer, a CNS disease, or cancer.
[0028] Preferred central nervous system metastases among cancers include brain metastases of cancer, meningeal metastases of cancer, glioma, DIPG and glioblastoma.
[0029] Preferred diseases are brain cancer, lung cancer, colon cancer, breast cancer, prostate cancer, liver cancer, membranous adenocarcinoma, kidney cancer, lymphoma, ovarian cancer, stomach cancer, skin cancer, bone cancer, glioma, neuroblastoma, hepatocellular carcinoma, papillary renal cell carcinoma or head and neck squamous cell carcinoma.
[0030] Preferably, the disease is non-small cell lung cancer (NSCLC).
[0031] Preferably, the disease is non-small cell lung cancer (NSCLC) with brain metastases.
[0032] Preferably, the disease is non-small cell lung cancer (NSCLC) with leptomeningeal metastases.
[0033] Preferably, the disease is glioma.
[0034] Preferably, the disease is glioblastoma.
[0035] Preferably, the disease is DIPG.
[0036] In another aspect, the present invention relates to a method for treating a disease or disease symptom in a subject in need thereof, the method comprising administering to the subject an effective amount of any compound of the general formula herein or a pharmaceutically acceptable salt, solvate or hydrate thereof (or a combination thereof). These diseases or disease symptoms can be any of those diseases for the DNA damage response pathway regulated by ATM protein kinase, particularly the repair of DNA double-strand breaks caused by radiation or other agents. These diseases or disease symptoms can be, for example, cancer or proliferative diseases or disorders (e.g., including those described herein).
[0037] Compared with the prior art, the present invention has the following beneficial effects:
[0038] 1) The 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinolin-2-one derivatives and pharmaceutically acceptable salts thereof of the present invention have the ability to penetrate the blood-brain barrier and can act as characteristic drugs of protein kinase inhibitors, in particular as characteristic drugs of proteins expressed by ATM, and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, glioma, glioblastoma and DIPG.
[0039] 2) The 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinoline-2-one derivatives and pharmaceutically acceptable salts thereof of the present invention have a low efflux rate, are not efflux substrates of human P-glycoprotein and breast cancer resistance protein, and have reduced resistance to efflux enzymes.
[0040] 3) 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinoline-2-one derivatives and pharmaceutically acceptable salts thereof have good pharmacokinetics (non-aldehyde oxidase substrates) and high biological activity and selectivity over other PIKKs (such as ATR, DNA-PK), which can minimize potential toxicity, reduce the burden of tablets and improve tablet intake compliance.
[0041] 4) The 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c]quinoline-2-one derivatives and pharmaceutically acceptable salts thereof of the present invention have low risk of inhibiting ion channels such as hERG, good safety and good compatibility with other agents, and low risk of potential drug-drug interaction tendency and time-dependent inhibition tendency. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] In the accompanying drawings,
[0043] Figures 1A to 1CThe chemical structures of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (1); (R / S)-1-(1-ethyl-3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (2); (R / S)-1-(3,3-difluoro-1-isopropylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (3); (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (4); (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (5); (R / S)-1-(3,3-difluoro-1-(deuterated methyl)piperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (6); (R / S) -1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (7); (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(dimethylamino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (8); (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-(deuteratedmethyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (9); (R / S)-8-(6 (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (10); (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (11); (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(deuterated methoxy)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (12);(R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1R,5R / 1S,5S)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (13); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (14); (R)-1-(1-ethyl-3,3-difluoropiperidin-4-yl)-8-(6 1-(3,3-difluoro-1-isopropylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (16); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (17); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (18); -7-Fluoro-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (18); (R)-1-(3,3-difluoro-1-(deuterated methyl)piperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (19); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (20); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (21); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(dimethylamino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (21); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-(deuteratedmethyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (22); (R)-8-(6-cyclopropyloxypyridin-3-yl)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (23);(R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (24); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(deuterated methoxy)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (25); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1R,5R)-(2-methyl-2,6-diazabicyclo[3. 2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]piperidin-2-one (26); (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1S,5S)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]piperidin-2-one (27); (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]piperidin-2-one (28) ; (S)-1-(1-ethyl-3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (29); (S)-1-(3,3-difluoro-1-isopropylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (30); (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (31); (S) -1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (32); (S)-1-(3,3-difluoro-1-(deuterated methyl)piperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (33); (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (34);(S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(dimethylamino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (35); (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-(deuteratedmethyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (36 ); (S)-8-(6-cyclopropyloxypyridin-3-yl)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (37); (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5 -c]quinolin-2-one (38); (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(deuterated methoxy)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (39); (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1R,5R)-(2-methyl-2,6-diazabicyclo[3.2. 0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (40); (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1S,5S)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (41);
[0044] Figure 2 The chemical formula and synthesis of 3,3-difluoro-1-methylpiperidin-4-amine A6 and 1-benzyl-3,3-difluoropiperidin-4-amine A5′ are shown.
[0045] Figure 3 The chemical formulas and syntheses of 8-bromo-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one B5 and 8-bromo-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-(deuteratedmethyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one B5′ are shown.
[0046] Figure 4The chemical formula and synthesis of the following are shown: 8-bromo-1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one C5
[0047] Figure 5 The chemical formula and synthesis of the following are shown: 1-(3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one D7
[0048] Figure 6 The chemical formula and synthesis of the following are shown: 2-cyclopropyloxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine E3
[0049] Figure 7 The chemical formula and synthesis of the following are shown: 2-(deuterated methoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine F3
[0050] Figure 8 The chemical formula and synthesis of the following are shown: N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine G2
[0051] Fig. 9 The chemical formula and synthesis of the following are shown: N,N-dimethyl-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)azetidin-3-amine H2
[0052] Fig.10 The chemical formula and synthesis of the following are shown: 2-methyl-6-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-2,6-diazabicyclo[3.2.0]heptane I6
[0053] Fig.11 A general synthetic method for coupling boronate intermediates with aryl bromides is shown
[0054] Fig.12 Representative examples showing the general synthetic method using a boronate ester intermediate for coupling with an aryl bromide
[0055] Fig.13 A general method for the chiral separation of racemic products 1-13 is shown.
[0056] Fig.14 Representative examples showing the general method for chiral separation of racemic products
[0057] Fig.15 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (1)
[0058] Fig.16 The chemical formula and synthesis of the following are shown: (R / S)-1-(1-ethyl-3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (2)
[0059] Fig.17 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-isopropylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (3)
[0060] Fig.18 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (4)
[0061] Fig.19 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (5)
[0062] Fig. 20 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-(deuterated methyl)piperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (6)
[0063] Fig.21 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (7)
[0064] Fig. 22The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(dimethylamino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (8)
[0065] Fig.23 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-(deuteratedmethyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (9)
[0066] Fig.24 The chemical formula and synthesis of the following are shown: (R / S)-8-(6-cyclopropyloxypyridin-3-yl)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (10)
[0067] Fig.25 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (11)
[0068] Fig.26 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(deuterated methoxy)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (12)
[0069] Fig. 27 The chemical formula and synthesis of the following are shown: (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1R,5R / 1S,5S)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (13) DETAILED DESCRIPTION
[0070] The terms of the present invention are explained as follows:
[0071] The terms "ameliorating," "treating," and "treating" are used interchangeably and refer to reducing, inhibiting, preventing, or stabilizing the occurrence or progression of a disease (eg, a disease or disorder described herein), in addition to, but not limited to, a therapeutic benefit and / or a prophylactic benefit.
[0072] "Disease" means any disorder or condition that damages or interferes with the normal function of cells, organs or tissues.
[0073] "Marker" refers to any change associated with a disease or disorder. For example, any protein or polynucleic acid whose expression level or activity is changed and associated with a disease or disorder.
[0074] In this context, "including", "containing" and "having" and similar terms have the meanings ascribed to them in patent law; "consisting essentially of" or "substantially" have the same meanings as ascribed to them in patent law, and the term is open, allowing the existence of objects other than the referenced objects, as long as the basic features or new features of the referenced objects are not changed by the existence of objects other than the referenced objects, but does not include the implementation of prior art.
[0075] As used herein, the terms "antagonist" and "inhibitor" are used interchangeably and refer to the ability of a compound or agent to inhibit the biological function of a target protein or polypeptide, such as by inhibiting the activity or expression of the protein or polypeptide. Although some antagonists herein interact with specific target proteins or polypeptides (e.g., bind ATM), these compounds also inhibit the biological activity of the target protein or polypeptide by interacting with other members of the signal transduction pathway of the targeted protein or polypeptide, including those members within the definition of inhibiting tumor development, growth or disseminated tumor development, or tumor development associated with an unwanted immune response manifested by an autoimmune disease.
[0076] As used herein, the terms "anticancer agent," "antitumor agent," or "chemotherapeutic agent" refer to any agent useful for treating a neoplastic disorder. One class of anticancer agents includes chemotherapeutic agents. "Chemotherapy" refers to one or more chemotherapeutic agents and / or other agents administered in a variety of ways, including intravenous, oral, subcutaneous, intramuscular, intraperitoneal, intravesical, transdermal, buccal, or by inhalation.
[0077] As used herein, the term "cell proliferation" refers to an increase in cell number due to cell division as well as cell growth (eg, increased size) consistent with proliferation signals in cell morphology.
[0078] As used herein, the term "co-administration" refers to the simultaneous use of two or more drugs, as well as the co-presence of a composition of two or more agents, as well as administration of two or more drugs and / or their metabolites at different times or separately.
[0079] As used herein, the term "effective amount" or "effective therapeutic amount" refers to an amount of a compound or pharmaceutical composition described herein that is sufficient to achieve the intended use, including but not limited to treating a disease. In some embodiments, the amount is detected to be effective for: killing cancer cells, or inhibiting the growth or spread of cancer cells; the size or number of tumors; or the severity level, stage and progression of cancer. The amount of effective treatment may vary depending on the intended application, such as in vitro or in vivo, the condition and severity of the disease, the age, body weight or mode of administration of the subject. The term also applies to doses that will induce target cells, for example, by reducing cell migration through a specific response. The specific dose will depend on, for example, the specific compound selected, the subject species and its age / existing health status or health status, the route of administration, the severity of the disease, in combination with other agents, the time of administration, the tissue to which it is administered, and the administration device.
[0080] As used herein, the term "therapeutic effect" includes therapeutic benefit and / or prophylactic benefit. Prophylactic effect includes delaying or eliminating the onset of a disease or condition, delaying or eliminating the onset of symptoms of a disease or disorder, slowing, stopping or reversing a disease or condition, or any combination thereof.
[0081] As used herein, the term "signal transduction" is the process of delivering stimulatory or inhibitory signals to cells to initiate responses within the cells. A "modulator" of a signal transduction pathway refers to a compound that modulates one or more activities of cellular proteins mediated by a particular signal transduction pathway. A "modulator" can increase (agonist) the activity of a signaling molecule or inhibit (antagonist) the activity of a signaling molecule.
[0082] As used herein, the term "selective inhibition" refers to the ability of a compound to selectively reduce target signaling activity compared to off-target target activity, either through direct interaction or indirect interaction. For example, the activity of a compound selectively inhibiting ATM is at least about 2 times, about 3 times, about 5 times, about 10 times, about 20 times, about 50 times, about 100 times, or more than the activity of ATR.
[0083] As used herein, the term "radiation therapy" refers to exposure of a subject to radiation emitters such as, but not limited to, alpha particles emitting radionuclear elements (e.g., actinium and thorium radionuclear elements) (e.g., beta emitters), conversion electron emitters (e.g., strontium-89 and samarium 153-EDTMP), or high energy radiation including, but not limited to, X-rays, gamma rays, and neutrons.
[0084] The term "subject" as used herein includes, but is not limited to, humans (e.g., any age group, such as male or female (e.g., infants, children, teenagers) or adult subjects (e.g., young, middle-aged or elderly)) and / or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, sheep, goats, pigs, horses, cats and / or dogs; and / or birds, including commercially relevant birds such as chickens, geese, quail, ducks and / or turkeys.
[0085] As used herein, the term "in vivo" refers to activities that occur within the body of a subject. Events in rodents such as rats, mice, guinea pigs, etc. are also included in vivo.
[0086] As used herein, the term "in vitro" refers to an event that occurs outside the body. For example, an in vitro test involves any detection that occurs outside the body. In vitro assays include cell assays based on living or dead cells, as well as cell-free assays for non-intact cells.
[0087] The term "compound" as used herein is also intended to include salts of the general formula herein. The term also includes any solvates, hydrates and polymorphs of any of the above substances. Certain aspects of the invention described in this application should not be construed as specific references to "solvates," "hydrates," or "polymorphs." In other aspects of the invention where the term "compound" is used without mentioning these other forms, it is not intended to exclude such forms.
[0088] Salts of the compounds of the invention are formed between an acidic group and a basic group (eg an amino functional group) of the compound. According to another preferred embodiment, the compound is a pharmaceutically acceptable acid addition salt.
[0089] As used herein, the term "pharmaceutically acceptable" refers to pharmaceutical compositions that are suitable for use in contact with human and other mammalian tissues without reasonable toxicity, irritation, allergic response, etc. and with reasonable benefits / risks over the components. "Pharmaceutically acceptable salt" refers to any non-toxic salt that, when administered to a recipient, can directly or indirectly provide a compound of the present invention.
[0090] Acids commonly used to form pharmaceutically acceptable salts include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, hydroiodic acid and phosphoric acid, and organic acids such as trifluoroacetic acid, citric acid, maleic acid, oxalic acid, picroacetic acid, adipic acid, alginic acid, aspartic acid, sulfuric acid, boric acid, butyric acid, valeric acid, camphoric acid, camphor thiocyanate, digluconic acid, dodecyl sulfate, pivalic acid, formic acid, fumaric acid, hydroiodic acid, benzoic acid, 2-hydroxy-ethanesulfonic acid, fumaric acid, stearic acid. , lactobionic acid, propionic acid lauric acid, oleic acid, nicotinic acid, lactic acid cinnamic acid, succinic acid, mandelic acid, malic acid, tartaric acid, tartaric acid, lactic acid, pyruvic acid, pectic acid, methanesulfonic acid, pamoate, benzenesulfonic acid, persulfate, palmitic acid, malonic acid, glycerophosphoric acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, salicylic acid, ascorbic acid, 3-phenylpropionic acid, gluconic acid, glucuronic acid, phosphoric acid, glutamic acid, ethanesulfonic acid, p-bromobenzenesulfonic acid and carbonic acid, as well as related inorganic and organic acids.
[0091] As used herein, the term "hydrate" refers to a compound comprising a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. As used herein, the term "solvate" refers to a compound comprising a stoichiometric or non-stoichiometric amount of a solvent (such as water, dichloromethane, 2-propanol, acetone, methanol, ethanol, etc.) bound by non-covalent intermolecular forces. Pharmaceutically acceptable solvates and hydrates are complexes that may contain, for example, 1 to about 100, or 1 to about 10, or 1 to about 4, about 3, or about 2 solvent molecules or water molecules. It should be understood that the term "compound" as used herein includes solvates, hydrates, and mixtures thereof of the compound and the compound.
[0092] As used herein, the term "polymorph" refers to a solid crystalline form of a compound or a complex thereof. Different polymorphs of the same compound may exhibit different physical, chemical, and / or spectral properties. Different physical properties include, but are not limited to, stability (e.g., heat, light, or moisture), density, hygroscopicity, solubility, compressibility, and dissolution rate.
[0093] As used herein, the term "isomer" is a different compound with the same molecular formula. "Stereoisomers" are isomers that only have atoms arranged in different ways. As used herein, the term "isomer" includes any and all geometric isomers and stereoisomers. For example, "isomers" include the geometric double bonds of cis-isomers and trans-isomers, also known as E-isomers and Z-isomers; R-enantiomers and S-enantiomers; diastereomers, (D) isomers and (L) isomers, their racemic mixtures, and other mixtures thereof.
[0094] Double bonds around carbon-carbon substituents are designated as either the "Z" or "E" configuration, wherein the terms "Z" and "E" are used according to IUPAC standards. Unless otherwise noted, structures depict both the "E" isomer and the "Z" isomer.
[0095] Substituents that can be replaced around a carbon-carbon double bond may be referred to as "cis" or "trans," where "cis" refers to substituents on the same side of the double bond, and "trans" refers to substituents on both sides. The arrangement of the surrounding carbon ring of the substituents may also be designated as "cis" or "trans." The term "cis" refers to substituents on the same side in the plane of the ring, and the term "trans" refers to substituents on both sides of the plane of the ring. A mixture of substituents on the same side and on opposite sides of two ring planes is represented as "cis / trans."
[0096] The term "enantiomer" as used herein is a pair of stereoisomers of non-overlapping mirror planes that overlap each other. A mixture of enantiomers in any ratio can be referred to as a "racemic" mixture. The term "(±)" is used to designate a racemic mixture as being suitable. "Diastereomers" refers to mirror images with at least two asymmetric atoms but their stereoisomers are different from each other. Absolute stereochemistry is designated according to the Cahn-lngal-Prelog RS system. When a compound is an enantiomer, the stereochemistry of each chiral carbon can be designated as R or S. The absolute configuration of a compound is unknown and can be designated as (+) or (-), depending on the direction of rotation of polarized light in the sodium D line (right or left) wavelength. Some of the substances described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms, and the absolute stereochemistry of each asymmetric atom (R)- or (S)- includes all such possible isomers, including racemic mixtures, optically pure forms, and intermediate mixtures. Optically active (R)- and (S)- may also be prepared using chiral synthetic methods or chiral reagents, or by conventional techniques.
[0097] The term "enantiomeric excess" as used herein can be calculated using the formula shown below. In the example shown below, the composition contains 90% of one enantiomer, such as the S enantiomer, and contains 10% of another enantiomer, such as the R enantiomer.
[0098] ee value = (90-10) / 100 = 80%.
[0099] Thus, a composition containing 90% of one enantiomer and 10% of another enantiomer is considered to have an enantiomeric excess of 80%. Some compositions described herein contain at least about 50% enantiomeric excess, about 75%, about 90%, about 95%, or about 99% of the S enantiomer. In other words, the composition comprises an enantiomeric excess of the S enantiomer among the R enantiomers. In other embodiments, some compositions described herein contain at least about 50% enantiomeric excess, about 75%, about 90%, about 95%, or about 99% of the R enantiomer. In other words, the composition comprises an enantiomeric excess of the R enantiomer among the S enantiomers. For example, in some embodiments, an isomer / enantiomer may provide an ee value of the corresponding enantiomer, and may also be referred to as "optically enriched," "enantiomerically enriched," "enantiomerically pure," and "non-racemic," which are used interchangeably herein. These terms refer to an enantiomer having a weight percentage greater than the amount of a control mixture of the composition, rather than greater than the amount of a racemic composition of one enantiomer (e.g., greater than a 1:1 weight ratio). For example, the enantiomer of the S enantiomer is present at about 75% by weight of the enantiomer, e.g., greater than about 50% by weight of the compound, at least about 80% by weight. In some embodiments, enrichment is greater than about 80% by weight, providing "substantially enantiomerically enriched," "substantially enantiomerically pure," or "substantially non-acidic" means that the weight of the enantiomer relative to one of the other enantiomers has at least 85% of the composition, such as at least about 90% by weight of the preparation, and further, for example, at least about 95% by weight. In certain embodiments, provided herein is a compound that can be present in an amount of about 90% by weight of at least one enantiomer. In other embodiments, the compound can be present in an amount of at least about 95% by weight, about 98% by weight, or about 100% by weight of an enantiomer. In some embodiments, the compound is a (S)-racemic and (R)-racemic mixture. In other embodiments, a method is provided in which the single compound (S) in the mixture is mainly a mixture of compounds, or (R)-is a mixture of compounds that are mainly present. For example, the compound mixture is greater than about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5% or more.In other embodiments, the mixture of compounds has an (S)-enantiomeric excess of greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 70% to about 99.5%, greater than about 75% to about 99.5%, greater than about 80% to about 99.5%, greater than about 85% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or greater. In other embodiments, the compound mixture (R)-enantiomeric purity is greater than about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5%, or more. In other embodiments, the mixture of compounds has an (R)-enantiomeric excess of greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 70% to about 99.5%, greater than about 75% to about 99.5%, greater than about 95% to about 99.5%, greater than about 85% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or more.
[0100] In other embodiments, the compound mixture contains the same chemical entity except for its stereochemical orientation, i.e., except for (S)- or (R)-. For example, if a -CH(R)- unit is present in the compound, and R is not hydrogen, then -CH(R)- and (S)- or (R)- stereochemical orientations are the same chemical entity. In some embodiments, the (S)-isomers in the mixture of the same chemical entities are present in an (S)-enantiomeric excess of greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 65% to about 99.5%, greater than about 90% to about 99.5%, greater than about 90% to about 99.5%, greater than about 90% to about 99.5%, greater than about 90% to about 99.5%, to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or more.
[0101] In another embodiment, the (R)-isomer is present at about 55%, about 60%, about 65%, about 90%, about 95%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.5% or more of the same chemical entity (except for its stereochemical orientation) relative to the (S)-isomer. In some embodiments, the (R)-enantiomeric excess in a mixture of identical chemical entities (except for their stereochemical orientation) is greater than about 55% to about 99.5%, greater than about 60% to about 99.5%, greater than about 75% to about 99.5%, greater than about 75% to about 99.5%, greater than about 75% to about 99.5%, greater than about 90% to about 99.5%, greater than about 95% to about 99.5%, greater than about 96% to about 99.5%, greater than about 97% to about 99.5%, greater than about 98% to greater than about 99.5%, greater than about 99% to about 99.5%, or more.
[0102] Enantiomers may be separated from racemic mixtures by any method known to those skilled in the art including chiral high performance liquid chromatography (HPLC), chiral salt formation and crystallization, or non-synthetic synthesis.
[0103] Optical isomers can also be obtained by cracking the racemic mixture (e.g., by forming diastereoisomeric salts) in a conventional manner with an optically active acid or base. Examples of suitable acids include, but are not limited to, tartaric acid, diacetyl, dibenzoyl, dimethoxytartaric acid, and camphorsulfonic acid. Separation of isomers from a mixture of optically active bases of these salts can be achieved by diastereoisomeric crystallization. Alternatively, the reaction of an open compound with an optically pure acid or optically pure isocyanate in an activated form involves the synthesis of covalent diastereoisomeric molecules. Synthesized enantiomers can be separated by conventional methods (such as chromatography, distillation, crystallization, or sublimation), and then hydrolyzed to provide an enantiomer-enriched compound. Optically active compounds can also be obtained by using active materials. In some embodiments, these isomers can be in the form of free acids, free bases, esters, or salts.
[0104] In certain embodiments, the pharmaceutically acceptable form is a tautomer. As used herein, the term "tautomer" is a type of isomer, which includes at least one form of migration and change of two or more interconverted compounds derived from hydrogen atoms and covalent bonds (e.g., single bonds and double bonds, triple bonds and single bonds, or vice versa). "Tautomerism" includes proton or proton migration tautomerism, which is considered to be a subset of acid-base chemical formulas. "Proton transfer tautomerism" involves proton migration with bond changes. The exact ratio of tautomers depends on several factors, including temperature, solvent and pH. Among them, tautomerism is possible (e.g., in solution), and the chemical equilibrium of tautomers can be reached. Tautomerism (i.e., providing a reaction of tautomer pairs) can be catalyzed by acid or base, or can occur in the presence or absence of external reagents. Such as tautomeric adducts include but are not limited to ketones and enols; amides and imides; enamines and imines; and one form of enamine with different forms of enamine. A specific example of ketone and enol tautomers is pentane-2,4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerism is phenol and ketone tautomerism. A specific example of phenol and ketone tautomers is pyridine-4-phenol and pyridine-4-(1H)-one tautomers.
[0105] Unless otherwise specified, it is intended that structures described herein include compounds that exist only with one or more isotopically enriched atoms. For example, the compound has a structure in which one hydrogen is replaced by deuterium or tritium, or carbon 13 or carbon 14 is enriched within the disclosed range.
[0106] The present disclosure also includes those "isotopically labeled derivatives" which are pharmaceutically acceptable forms of those compounds described herein except that one or more atoms have an atomic mass different from that usually found in nature. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 18 F and 36 Cl. Certain isotopically labeled disclosed compounds (e.g., labeled 3 H and 14 C) are used to determine compound and / or substrate tissue distribution. 3 H) and carbon 14 (i.e. 14 C) isotopes can be easily prepared and tested. In addition, heavier isotopes such as deuterium (i.e. 2H or D) substitution can provide certain therapeutic advantages caused by greater metabolic stability (e.g., increasing half-life in vivo or reducing dosage requirements). Isotope-labeled disclosed compounds can generally be prepared by replacing isotope-labeled reagents with non-isotope-labeled reagents. In some embodiments, provided herein are compounds that may also include one or more non-natural atomic isotopes to form such compounds. All isotope variants of disclosed compounds are used herein within the scope of the present disclosure, whether or not they are radioactive. In some embodiments, radiolabeled compounds can be used to study the metabolism and tissue distribution of compounds to change metabolic pathways or rates or other biological functions.
[0107] As used herein, the term "stereoisomer" refers to both enantiomers and diastereomers.
[0108]
[0046] As used herein, the term "halo" or "halogen" refers to any radical of fluorine, chlorine, bromine and iodine.
[0109] As used herein, the term "alkyl" refers to a straight or branched chain consisting of carbon and hydrogen atoms, excluding unsaturated hydrocarbon chains having 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms. "Lower alkyl" refers to an alkyl group having 1 to 4 carbon atoms (including 1 and 4 carbon atoms).
[0110] The term "arylalkyl" refers to a moiety in which an alkyl hydrogen atom is replaced with an aryl group.
[0111] The term "alkenyl" refers to a straight or branched hydrocarbon chain having 2 to 10, preferably 2 to 4 carbon atoms, with at least one double bond. When the alkenyl group is attached to a nitrogen atom, it is preferred that such groups are not directly attached through a carbon having a double bond.
[0112] The term "alkoxy" refers to an -O-alkyl group containing 1 to 10 carbon atoms connected to the parent molecular structure via an oxygen, and these carbon atoms are from straight chain, branched chain, saturated cyclic structure and their combination. For example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclohexyloxy, etc. "Lower alkoxy" refers to an alkoxy group containing one to six carbons.
[0113] The term "alkynyl" refers to a straight or branched hydrocarbon chain of 2 to 10 carbon atoms (i.e., C2-10 alkynyl), preferably 2 to 4 carbon atoms, containing at least one triple bond, a straight chain hydrocarbon group. When an alkynyl group is attached to a nitrogen atom, it is preferred that such groups are not directly attached through a carbon having a triple bond.
[0114] The term "alkylene" refers to a divalent straight chain bridge having 1 to 5 carbon atoms connected by a single bond (e.g., -(CH2) x -, wherein x is 1 to 5), which may be substituted by 1 to 3 alkyl substituents.
[0115] The terms "cycloalkyl" and "cycloalkenyl" as used herein include saturated and partially saturated cyclic hydrocarbon alkyl groups having 3 to 12 carbon atoms, preferably 3 to 8 carbon atoms, and more preferably 3 to 6 carbon atoms.
[0116] The term "Ar" or "aryl" refers to an aromatic cyclic group containing 6 to 14 carbon atoms (eg, 6-membered monocyclic ring, 10-membered bicyclic ring). Exemplary aryl groups include phenyl, naphthyl, and biphenyl.
[0117] The term "heterocycle", "heterocyclic" or "heterocyclyl" refers to a fully saturated or partially unsaturated cyclic group, such as a 3- to 7-membered monocyclic, 7- to 12-membered bicyclic, 15-membered tricyclic ring system having at least one heteroatom in at least one ring, wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent. Each ring in the heterocyclic group containing heteroatoms may have 1, 2, 3 or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and / or sulfur atoms, wherein the nitrogen heteroatoms and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatoms may be optionally quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system.
[0118] The term "substituent" refers to a group that is "substituted" on any functional group described herein, such as an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, arylbase, heterocyclyl, or heteroaryl. Suitable substituents include, but are not limited to, halogen, CN, NO2, OR, SR, S(O)2OR, NRR', C1-C2 perfluoroalkyl, C1-C2 perfluoroalkoxy, (NR)NRR', N(NR)NRR', N(NR)NRR', N(NR)NRR', C(O)(O)R", S(O)2R", R', C(O)R', C(O)R", N(R)(CH2) n OH, (CH2) n OR, (CH2) nC(O)NRR', NRS(O)2R', wherein n is independently 0 to 6, including 0 and 6. Each R is independently hydrogen, C1-C4 alkyl or C3-C6 cycloalkyl. Each R' is independently hydrogen, alkenyl, alkynyl, C3-C6 cycloalkyl, aryl, heterocyclyl, heteroaryl, C1-C4 alkyl, or C3-C5 cycloalkyl, aryl, heterocyclyl or heteroaryl substituted C-C4 alkyl. Each R" is independently C3-C6 cycloalkyl, aryl, heterocyclyl, heteroaryl, C1-C4 alkyl, or is substituted by C3-C6 cycloalkyl, aryl, heterocyclyl or heteroaryl, C1-C4 alkyl. Each C3-C5 cycloalkyl, aryl, heterocyclyl, heteroaryl and C1-C4 alkyl in each R, R' and R" may be optionally substituted by halogen, CN, C1-C4 alkyl, OH, C1-C4 alkoxy, NH2, C1-C4 alkylamino, C1-C4 dialkylamino, C1-C2 perfluoroalkyl, C1-C2 perfluoroalkoxy or 1,2-methylenedioxy.
[0119] The term "oxo" refers to an oxygen atom which when attached to carbon forms a carboxyl, when attached to nitrogen forms an N-oxide, and when attached to sulfur forms a sulfoxide or sulfone.
[0120] The term "acyl" refers to an alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heterocyclylcarbonyl or heteroarylcarbonyl substituent, any of which may be further substituted with a substituent.
[0121] The term "CDCl3" refers to deuterated chloroform.
[0122] The term "DMSO-d6" refers to deuterated dimethyl sulfoxide
[0123] The term "LC-MS:(ESI)" refers to electrospray ionization liquid chromatography mass spectrometry
[0124] As used herein, the term "alteration" is defined as a change in a relative physiological state. Exemplary alterations include mutation, deletion, fusion with other proteins, overexpression or underexpression.
[0125] The description of enumerated chemical groups in any definition of a variable herein includes defining the variable as any single group or combination of enumerated groups. The description of an embodiment of a variable herein includes that embodiment as any single embodiment, or in combination with any other embodiment or portion thereof. The description of an embodiment of that embodiment includes that embodiment as any single embodiment, or in combination with any other embodiment or portion thereof.
[0126] The compounds of the present invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers, and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention. The compounds of the present invention may also exist in various tautomeric forms, in which case the present invention expressly includes all tautomeric forms of the compounds described herein. All such isomeric forms of such compounds are included in the present invention. All crystalline forms of the compounds described herein are expressly included in the present invention.
[0127] The compounds of the present invention:
[0128] In one aspect, the present invention provides a compound of formula (I)
[0129] or a salt thereof; or a hydrate, solvate or polymorph thereof; wherein:
[0130] wherein R1 is independently selected from OC1-3 alkyl, OC3-5 cycloalkyl, OC1-C3 deuterated alkyl, dialkylamine, substituted C4-C6 cyclic amine or diazabicyclic amine;
[0131] R2 is independently selected from hydrogen or fluorine;
[0132] R3 is independently selected from methyl or deuterated methyl;
[0133] R4 is independently selected from C1-C3 alkyl or C1-C3 deuterated alkyl;
[0134] In another embodiment, the present invention provides a compound of formula (II):
[0135] or a salt thereof; or a hydrate, solvate or polymorph thereof; wherein:
[0136] R1 is independently selected from OC1-3 alkyl, OC3-5 cycloalkyl, OC1-C3 deuterated alkyl, dialkylamine, substituted C4-C6 cyclic amine or diazabicyclic amine;
[0137] R2 is independently selected from hydrogen or fluorine;
[0138] R3 is independently selected from methyl or deuterated methyl;
[0139] R4 is independently selected from C1-C3 alkyl or C1-C3 deuterated alkyl;
[0140] In another embodiment, the present invention provides a compound of formula (III):
[0141] or a salt thereof; or a hydrate, solvate or polymorph thereof; wherein:
[0142] R1 is independently selected from OC1-3 alkyl, OC3-5 cycloalkyl, OC1-C3 deuterated alkyl, dialkylamine, substituted C4-C6 cyclic amine or diazabicyclic amine;
[0143] R2 is independently selected from hydrogen or fluorine;
[0144] R3 is independently selected from methyl or deuterated methyl;
[0145] R4 is independently selected from C1-C3 alkyl or C1-C3 deuterated alkyl;
[0146] Representative compounds of the present invention are Figures 1A to 1C Compounds 1 to 41 are shown. In these examples, unless explicitly stated, the stereochemistry of the chiral carbon atoms is independently R / S, R or S. The structures described herein include reference Figures 1A to 1C The structures of the following compounds 1 to 41 may be certain NH, NH2 (amino) and OH (hydroxyl) groups, wherein the corresponding hydrogen atoms are not explicitly shown; however, they will be read as NH, NH2 or OH as appropriate. In some structures, drawing a rod-shaped bond means a methyl group.
[0147] Representative compounds of the present invention are as follows:
[0148] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (1)
[0149] (R / S)-1-(1-ethyl-3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (2)
[0150] (R / S)-1-(3,3-difluoro-1-isopropylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (3)
[0151] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (4)
[0152] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (5)
[0153] (R / S)-1-(3,3-difluoro-1-(deuterated methyl)piperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (6)
[0154] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (7)
[0155] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(dimethylamino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (8)
[0156] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-(deuterated methyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (9)
[0157] (R / S)-8-(6-cyclopropyloxypyridin-3-yl)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (10)
[0158] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (11)
[0159] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(deuterated methoxy)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (12)
[0160] (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1R,5R / 1S,5S)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (13)
[0161] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (14)
[0162] (R)-1-(1-ethyl-3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (15)
[0163] (R)-1-(3,3-difluoro-1-isopropylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (16)
[0164] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (17)
[0165] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (18)
[0166] (R)-1-(3,3-difluoro-1-(deuterated methyl)piperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (19)
[0167] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (20)
[0168] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(dimethylamino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (21)
[0169] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-(deuterated methyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (22)
[0170] (R)-8-(6-cyclopropyloxypyridin-3-yl)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (23)
[0171] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (24)
[0172] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(deuterated methoxy)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (25)
[0173] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1R,5R)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (26)
[0174] (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1S,5S)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (27)
[0175] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (28)
[0176] (S)-1-(1-ethyl-3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (29)
[0177] (S)-1-(3,3-difluoro-1-isopropylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (30)
[0178] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (31)
[0179] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (32)
[0180] (S)-1-(3,3-difluoro-1-(deuterated methyl)piperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (33)
[0181] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (34)
[0182] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(dimethylamino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (35)
[0183] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-(deuterated methyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (36)
[0184] (S)-8-(6-cyclopropyloxypyridin-3-yl)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (37)
[0185] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (38)
[0186] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(deuterated methoxy)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (39)
[0187] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1R,5R)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (40)
[0188] (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1S,5S)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (41)
[0189] The synthesis of compounds of the general formula herein can be readily performed by ordinary synthetic chemists, such as the relevant methods and intermediates disclosed herein. Each patent, patent application and publication mentioned herein, whether in traditional journals or only on the Internet, is incorporated herein by reference in its entirety.
[0190] Other methods for synthesizing compounds of the general formula herein can be readily adapted from the references cited herein. Variations on these procedures and their optimization are within the capabilities of the ordinary skilled artisan.
[0191] The specific patterns and compounds shown above are not intended to be limiting. The chemical structures in the scheme depict a number of variables, wherein the chemical groups defined in the corresponding positions of the compounds of the formula (parts, atoms, etc.) are used to sterilize them accordingly, whether or not they are represented by the same variable name (e.g., R1, R2, R, R', R", X, etc.), the suitability of the chemical groups in the compound structure for synthesizing another compound structure is within the capabilities of those of ordinary skill in the art. Other methods for compounds of the general formula and their synthetic precursors, including those not explicitly shown in the present disclosure, are within the scope of the chemical means of those of ordinary skill in the art. Methods for optimizing reaction conditions in order to reduce competitive by-products are known in the art. The methods described herein may additionally include steps before or after the steps described herein to explicitly incorporate or remove suitable protecting groups, thereby ultimately enabling the synthesis of the compounds described herein. In addition, the various synthetic steps may be performed in a variable order or sequence to obtain the desired compounds.
[0192] The methods described herein contemplate converting a compound of one formula into a compound of another formula. Conversion methods refer to one or more chemical transformations that can be performed in situ or separated from intermediate compounds. The conversion may include reacting the starting compound or intermediate with additional reagents using techniques and protocols known in the art, including those described in the references cited herein. The intermediates may be purified (e.g., filtered, distilled, sublimed, crystallized, ground, solid phase extracted, and chromatographically separated) or used without purification.
[0193] Combinations of substituents and variables contemplated by this invention are only those that result in the formation of stable compounds.
[0194] The present invention also provides a composition comprising an effective amount of a compound of any general formula herein, or, if applicable, a pharmaceutically acceptable salt, solvate, hydrate or polymorph of the compound; and an acceptable carrier. Preferably, the composition of the present invention is formulated for pharmaceutical use (pharmaceutical composition), wherein the carrier is a pharmaceutically acceptable carrier. In view of compatibility with other ingredients of the formulation and in the case of a pharmaceutically acceptable carrier, the carrier must be "acceptable" and will not damage its receptor in the amount commonly used in the drug.
[0195] "Pharmaceutically acceptable carrier"; or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. Pharmaceutically acceptable carriers or excipients do not destroy the pharmacological activity of the disclosed compounds and are nontoxic when administered in doses sufficient to deliver the compound. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active ingredient, the use of therapeutic compositions as disclosed herein is contemplated. Examples of pharmaceutically acceptable carriers and excipients include, but are not limited to, sugars such as lactose, sucrose and glucose; starches such as potato starch and corn starch; cellulose and its derivatives such as sodium carboxymethylcellulose, cellulose acetate and ethylcellulose; gelatin; tragacanth powder; talc; malt; cocoa butter and suppository waxes; oils such as peanut oil, safflower oil, cottonseed oil, olive oil, sesame oil, corn oil and soybean oil; glycols such as polyethylene glycol and propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; aldehydes; phosphates; phosphate buffers; nontoxic compatible lubricants, such as lauryl sulfate Sodium and magnesium stearate; coloring agents; coating agents; release agents; sweeteners, flavoring agents and fragrances; (SEDDS), such as vitamin E polyethylene glycol 1000 succinate; surfactants for pharmaceutical dosage forms, such as Tween or other similar polymer delivery matrices; serum proteins, such as human serum albumin; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water, salts or electrolytes, such as protamine sulfate, potassium hydrogen phosphate, disodium hydrogen phosphate, sodium chloride and zinc salts; colloidal silicon dioxide; magnesium trisilicate; polyvinyl pyrrolidone; cellulose-based materials; polyacrylates; waxes; and polyethylene-polyoxypropylene-block polymers. Cyclodextrins, such as α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, or chemically modified derivatives, such as hydroxyalkyl cyclodextrins including 2-hydroxypropyl cyclodextrin and 3-hydroxypropyl cyclodextrin or other solubilizing derivatives, to improve the delivery of the compound.
[0196] The pharmaceutical compositions of the present invention can be administered in solid or liquid form, including oral administration, for example, irrigation (aqueous or non-aqueous solutions or suspensions), tablets (e.g., those for oral subcutaneous and systemic absorption), hard or soft capsules, pills, syrups, powders, granules, pastes for application to the tongue, duodenal routes; parenteral administration, including intravenous, intraarterial, subcutaneous, intramuscular, for example, as creams, ointments, gels, aqueous or oily solutions or suspensions (e.g., as creams, ointments, gels or vaginal suppositories, creams or stents); sublingual administration; topical administration via a catheter or stent; intrathecally or nasally (e.g., as a fine powder) or by inhalation (e.g., as a fine powder or liquid aerosol).
[0197] Examples of suitable aqueous and non-aqueous carriers in pharmaceutical compositions include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and organic esters such as ethyl oleate. By using coating materials such as lecithin, by maintaining the desired particle size of the dispersion, and by using a surfactant to maintain appropriate fluidity. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifiers, dispersants, lubricants and / or antioxidants. The compounds described herein may be used to prevent the effects of microorganisms by including different antimicrobial agents and antifungal agents (e.g., parabens, chlorobutanol, phenol sorbic acid, etc.) to ensure. Isotonic agents such as sugars, sodium chloride, etc. may also be included in the composition. In addition, by including delayed absorption agents such as aluminum monostearate and gelatin, extended absorption of injectable drug forms may be achieved.
[0198] The method for preparing such preparations or compositions includes compounds as described herein, and / or steps associated with chemotherapeutic vehicles and optional one or more auxiliary components. Typically, the preparation is formed by uniformly structuring the compound disclosed herein with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, the product is molded. Unless any conventional excipient medium is incompatible with the compound provided herein, such as by interacting with any other component of a pharmaceutically acceptable composition to produce any undesirable biological effect or harmful effect, the excipient is also intended to fall within the scope of the present disclosure.
[0199] In some embodiments, the concentration of one or more disclosed compounds may be less than about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 14%, about 13%, about 12%, about 11%, about 10%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, about 0.09%, about 0.08%, about 0.07%, about 0.06%, about 0.05%, about 0.04%, about 0.03%, about 0.1% or less. About 0.02%, about 0.01%, about 0.009%, about 0.008%, about 0.007%, about 0.006%, about 0.005%, about 0.004%, about 0.003%, about 0.002%, about 0.001%, about 0.0009%, about 0.0008%, about 0.0007%, about 0.0006%, about 0.0005%, about 0.0004%, 0.0003%, about 0.0002%, or about 0.0001% weight / weight ratio, weight / volume ratio, or volume / volume ratio.
[0200] In some embodiments, the concentration of one or more compounds disclosed herein may be greater than about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 18.5%, about 18.25%, about 17.5%, about 17.25%, about 17%, about 16.5%, about 16.25%, about 16%, about 15.5%, about 15.25%, about 15%, about 14.5%, about 14.25%, about 14%, about 13.5%, about 13.25%, about 13%, about 14.5%, about 14.25 ... 2.5%, about 12.25%, about 12%, about 11.5%, about 11.25%, about 11%, about 10.75%, about 10.5%, about 10%, about 9.75%, about 9.5%, about 9.25%, about 9%, about 8.75%, about 8.5%, about 8.25%, about 8%, about 7.75%, about 7.5%, about 7.25%, about 7%, about 6.75%, about 6.5%, about 6.25%, about 6%, about 5.75%, about 5.5%, about 5.25%, about 5%, about 4.75%, about 4 .5%, about 4.25%, about 4%, about 3.75%, about 3.5%, about 3%, about 2.75%, about 2.50%, about 2.25%, about 2%, about 1.75%, about 1.50%, about 1.25%, about 1%, about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, about 0.1%, about 0.09%, about 0.08%, about 0.07%, about 0.06%, about 0.05%, about 0.04%, about 0.03%, about 0.02%, about 0.01%, about 0.009%, about 0.008%, about 0.007%, about 0.006%, about 0.005%, about 0.004%, about 0.003%, about 0.002%, about 0.001%, about 0.0009%, about 0.0008%, about 0.0007%, about 0.0006%, about 0.0005%, about 0.0004%, about 0.0003%, about 0.0002%, about 0.0001%, about 0.0009%, about 0.0008%, about 0.0007%, about 0.0006%, about 0.0005%, about 0.0004%, about 0.0003%, about 0.0002%, or about 0.0001% weight / weight, weight / volume, or volume / volume.In some embodiments, the concentration of one or more compounds disclosed herein can range from about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% to about 30%, about 0.02% to about 20%, about 0.09% to about 24%, about 0.08% to about 23%, about 0.07% to about 22%, about 0.06% to about 24%, about 0.2% to about 20%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about 0.9% to about 12%, about 1% to about 10% weight / weight ratio, weight / volume ratio, or volume / volume ratio. In some embodiments, the concentration of one or more compounds disclosed herein may range from about 0.001% to about 10%, about 0.01% to about 5%, about 0.02% to about 4.5%, about 0.03% to about 4%, about 0.04% to about 3.5%, about 0.05% to about 3%, about 0.06% to about 2.5%, about 0.07% to about 2%, about 0.08% to about 1.5%, about 0.09% to about 1%, about 0.1% to about 0.9% weight / weight ratio, weight / volume ratio, or volume / volume ratio.
[0201] In some embodiments, the amount of one or more compounds disclosed herein can be equal to or less than about 10 grams, about 9.5 grams, about 9.0 grams, about 8.5 grams, about 8.0 grams, about 7.5 grams, about 7.0 grams, about 6.5 grams, about 6 grams, about 5.5 grams, about 5 grams, about 4.5 grams, about 4 grams, about 3.5 grams, about 3 grams, about 2.5 grams, about 2.0 grams, about 1.5 grams, about 1.0 grams, about 0.95 grams, about 0.9 grams, about 0.85 grams, about 0.8 grams, about 0.75 grams, about 0.7 grams, about 0.65 grams, about 0.6 grams, about 0.55 grams, about 0.5 grams, about 0.45 grams, about 0.4 grams, about 0.35 grams, about 0.3 grams, about 0.25 grams, about About 0.2 grams, about 0.15 grams, about 0.1 grams, about 0.09 grams, about 0.08 grams, about 0.07 grams, about 0.06 grams, about 0.05 grams, about 0.04 grams, about 0.03 grams, about 0.02 grams, about 0.01 grams, about 0.009 grams, about 0.008 grams, about 0.007 grams, about 0.006 grams, about 0.005 grams, about 0.004 grams, about 0.003 grams, about 0.002 grams, about 0.001 grams, about 0.0009 grams, about 0.0008 grams, about 0.0007 grams, about 0.0006 grams, about 0.0005 grams, about 0.0004 grams, about 0.0003 grams, about 0.0002 grams or about 0.0001 grams.In some embodiments, the amount of one or more compounds disclosed herein may exceed about 0.0001 gram, about 0.0002 gram, about 0.0003 gram, about 0.0004 gram, about 0.0005 gram, about 0.0006 gram, about 0.0007 gram, about 0.0008 gram, about 0.0009 gram, about 0.001 gram, 0.0015 gram, about 0.002 gram, about 0.0025 gram, about 0.003 gram, about 0.004 gram, about 0.005 gram, about 0.006 gram, about 0.007 gram, about 0.008 gram, about 0.009 gram, about 0.001 gram, 0.0015 gram, about 0.002 gram, about 0.0025 gram, about 0.003 gram, about 0.004 ... .0035 grams, about 0.004 grams, about 0.0045 grams, about 0.005 grams, about 0.0055 grams, about 0.006 grams, about 0.0065 grams, about 0.007 grams, about 0.0075 grams, about 0.008 grams, about 0.0085 grams, about 0.009 grams, about 0.0095 grams, about 0.01 grams, about 0.015 grams, about 0.02 grams, about 0.025 grams, about 0.03 grams, about 0.035 gram, about 0.04 gram, about 0.045 gram, about 0.05 gram, about 0.055 gram, about 0.06 gram, about 0.065 gram, about 0.07 gram, about 0.075 gram, about 0.08 gram, about 0.085 gram, about 0.09 gram, about 0.095 gram, about 0.1 gram, about 0.15 gram, about 0.2 gram, about 0.25 gram, about 0.3 gram, about 0.35 gram, about 0.4 gram, about 0.45 gram, about 0. ... .55 grams, about 0.6 grams, about 0.65 grams, about 0.7 grams, about 0.75 grams, about 0.8 grams, about 0.85 grams, about 0.9 grams, about 0.95 grams, about 1 gram, about 1.5 grams, about 2 grams, about 2.5 grams, about 3 grams, about 3.5 grams, about 4 grams, about 4.5 grams, about 5 grams, about 5.5 grams, about 6 grams, about 6.5 grams, about 7 grams, about 7.5 grams, about 8 grams, about 8.5 grams, about 9 grams, about 9.5 grams or about 10 grams.
[0202] In some embodiments, the amount of one or more compounds disclosed herein may range from about 0.0001 grams to about 10 grams, about 0.0005 grams to about 9 grams, about 0.001 grams to about 0.5 grams, about 0.001 grams to about 8 grams, about 0.005 grams to about 7 grams, about 0.01 grams to about 6 grams, about 0.05 grams to about 5 grams, about 0.1 grams to about 4 grams, about 0.5 grams to about 4 grams, or about 1 gram to about 3 grams.
[0203] In certain preferred embodiments, pharmaceutical compositions for oral administration comprise a compound as disclosed herein and a pharmaceutical excipient suitable for oral administration. In some embodiments, provided herein are pharmaceutical compositions for oral administration: (1) an optional effective amount of a disclosed compound; (2) an effective amount of one or more second agents; and (3) one or more pharmaceutically acceptable excipients for oral administration. In some embodiments, the pharmaceutical composition further comprises: (4) an effective amount of a third agent.
[0204] In some embodiments, the pharmaceutical composition can be a liquid pharmaceutical composition suitable for oral administration. Pharmaceutical compositions suitable for oral administration can be used as discrete dosage forms, such as capsules, cachets or tablets, or liquids, solutions, aerosol sprays or suspensions containing a predetermined amount of active ingredients of powder or granules, water or non-aqueous liquids, liquid emulsions in water, or water in liquid emulsions. Such dosage forms can be prepared by any pharmaceutical method, but all methods include the step of preparing the composition by uniformly and closely associating the active ingredient with a liquid carrier, liposomes or finely divided solid carriers or both. Typically, pharmaceutical compositions are formed by uniformly and closely mixing the active ingredient with a liquid carrier or finely divided solid carriers or both, and if necessary, the product is formed into a desired form. For example, a tablet can be one or more components that can be pressed or molded. Tablets can be formed by mixing a free-flowing form (such as an active ingredient in a powder or granule) optionally with an excipient (such as, but not limited to, a binder, a lubricant, an inert diluent and / or a surfactant or dispersant mixture) and pressing in an appropriate machine. Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. Tablets may optionally be uncoated, coated or notched, and may be formulated to provide a slow or controlled release of the active ingredient therein, thereby providing a sustained effect over a long period of time, such as glyceryl monostearate or glyceryl distearate. Preparations for oral use may also be hard gelatin capsules, in which the active ingredient may be mixed with an inert solid diluent (e.g., calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules, in which the active ingredient may be mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
[0205] Active ingredient can be closely combined with pharmaceutically acceptable carrier by conventional drug mixing technology. Carrier can take various forms, depending on the desired formulation application form. In the preparation of pharmaceutical compositions for oral dosage forms, any conventional pharmaceutical medium can be used as a carrier, such as water, glycol, oil, ethanol, flavoring agent, preservative, colorant and oral liquid preparation (such as liquid, solution and elixir) or aerosol, or carrier such as starch, sugar, microcrystalline cellulose, diluent, granule, lubricant, binder and disintegrant can be used for oral solid preparation. Lactose is not used in some embodiments. In some embodiments, compound can be mixed with lactose, sucrose, starch powder, cellulose ester of alkanoic acid, cellulose alkyl ester, talc, stearic acid, magnesium stearate, magnesium oxide, calcium phosphate, sodium phosphate, calcium sulfate, sodium sulfate, gelatin, gum arabic, sodium alginate, polyvinyl pyrrolidone and / or polyvinyl alcohol for further preparation. For example, when preparing solid oral preparations, suitable carrier also includes powder, capsule and tablet. In some embodiments, tablets may be coated by standard aqueous or nonaqueous techniques.
[0206] Suitable materials for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch or other starches, gelatin, natural binders and synthetic gums (such as gum arabic), sodium alginate, alginic acid, other alginates, powdered tragacanth gum, guar gum, cellulose and its derivatives (e.g., ethylcellulose, cellulose acetate, calcium carboxymethylcellulose, sodium carboxymethylcellulose), polyvinylpyrrolidone, cellulose, pregelatinized starch, hydroxypropyl methylcellulose, microcrystalline cellulose, and mixtures thereof.
[0207] Examples of suitable fillers for pharmaceutical compositions and dosage forms include, but are not limited to, talc, calcium carbonate (eg, granules or powder), microcrystalline cellulose, powdered cellulose, dextrose binders, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof.
[0208] Disintegrants can be used in pharmaceutical compositions as provided herein to provide tablets that disintegrate when exposed to an aqueous environment. Too much disintegrant may cause the tablet to disintegrate in the bottle. Too little may not be enough to disintegrate, and therefore may change the release rate and extent of the active ingredient of the dosage form. Therefore, the disintegrant should be sufficient, neither too little nor too much, so as not to release the active ingredient unfavorably. The amount of disintegrant will depend on the formulation and the mode of administration, and can be easily implemented by a person of ordinary skill in the art. About 0.5% by weight to about 15% by weight of disintegrant, or about 1% by weight to about 5% by weight of disintegrant can be used in the pharmaceutical composition. In order to form the disintegrant and dosage form of the pharmaceutical composition, the disintegrant includes but is not limited to agar, alginic acid, calcium carbonate, microcrystalline cellulose, cross-linked carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, sodium acetate, potato or tapioca starch, other starches, preformed starches, clays, other algae, other celluloses, gums or mixtures thereof.
[0209] Lubricants can be used to form pharmaceutical compositions, including but not limited to calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerol, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar or mixtures thereof. Lubricants also include, for example, silica gel, condensation type aerosol or mixtures thereof. Lubricants can be optionally added in an amount less than about 1% by weight of the pharmaceutical composition.
[0210] When aqueous suspensions and / or elixirs are used for oral administration, the active ingredient may be combined with various sweeteners or flavoring agents, colorants or dyes (e.g., emulsifying and / or suspending agents), diluents (e.g., water, ethanol, propylene glycol, glycerin, and combinations thereof).
[0211] Surfactants that can be used to form pharmaceutical compositions and dosage forms include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. Suitable hydrophilic surfactants may generally have an HLB value of at least about 10, and suitable lipophilic surfactants may generally have an HLB value of less than about 10. The empirical parameter used to characterize relative hydrophilicity and hydrophobicity is the hydrophilic-lipophilic balance value HLB ("HLB" value). The lower the HLB value, the more lipophilic or hydrophobic the surfactant is, and the greater the solubility in oil, while the higher the HLB value, the more hydrophilic the active agent is, and the greater the solubility in aqueous solution. Hydrophilic surfactants are generally considered to have an HLB value greater than about 10, however, for anionic, cationic or zwitterionic compounds, the HLB scale is generally not applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are those surfactants having an HLB value equal to or less than about 10. However, the HLB value of a surfactant is only a rough guide generally used in industrial, pharmaceutical and cosmetic emulsions.
[0212] The hydrophilic surfactant may be ionic or nonionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidates; fatty acid derivatives of amino acids, oligopeptides and polypeptides; derivatives of amino acids, oligopeptides and polypeptide glycerides; lecithin and phospholipids and their derivatives; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; sodium lauryl; acyl lactylates; monoacetylated and diacetylated monoglycerides and diglycerides of tartaric acid esters; succinylated monoglycerides and diglycerides; citric acid esters of monoglycerides and diglycerides; and mixtures thereof. Ionic surfactants include, but are not limited to, for example, lecithin, lysolecithin, phospholipids, lysolecithin and their derivatives; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; acyl lactylates; diacetylated tartaric acid esters of monoglycerides and diglycerides; succinylated monoglycerides and diglycerides; citric acid esters of monoglycerides and diglycerides; and mixtures thereof. Hydrophilic nonionic surfactants include, but are not limited to, alkyl glycosides; alkyl maltose; alkyl glucosides; lauroyl macrogol glycerides; polyoxyalkylene alkyl ethers, such as polyethylene glycol polyoxyalkylene alkylphenols, for example polyethylene glycol alkylphenols; polyoxyalkylene alkylphenol fatty acid esters, such as polyethylene glycol fatty acid monoesters and polyethylene glycol fatty acid diesters; glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters, for example polyethylene glycol sorbitan fatty acid esters; and glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols, polyoxyethylene sterols, derivatives thereof, etc.; polyoxyethylene vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; hydrophilic transesterification products of polyethylene glycol sorbitan fatty acid esters and polyols of at least one triglyceride, vegetable oil and hydrogenated vegetable oil. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol or a carbohydrate. Other hydrophilic nonionic surfactants include, but are not limited to, PEG-10 lauric acid, PEG-12 lauric acid, PEG-20 lauric acid, PEG-32 lauric acid, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate.PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-40 oleate, PEG-15 stearate, PEG-32 distearate lactone, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 trioleate, PEG-32 dioleate, PEG-20 glyceryl laurolactone, PEG-30 glyceryl laurate, PEG-20 glycerate, PEG-20 glyceryl oleate, PEG-30 glyceryl, PEG-30glyce, PEG-40 castor oil, PEG-40 castor oil, PEG-40 castor oil, PEG-40 castor oil, PEG-40 castor oil, PEG-40 castor oil, PEG-40 castor oil, PEG -40 castor oil, PEG-40 castor oil, PEG hydrogenated castor oil, PEG-60 corn oil, PEG-6 glyceryl / capric glyceride, PEG-8 capric / caprylic glyceride, polyglyceryl 1-10 laurate, PEG-30 cholesterol, PEG-25 phytosterols, PEG-30 soybean sterols, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearin, PEG-100 tocopheryl succinate, PEG-24 cholesterol, polysorbate 40, polysorbate 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonylphenol series, PEG 15-100 octylphenol series and poloxamer. Suitable lipophilic surfactants include, but are not limited to, for example, fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acid esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of monoglycerides and diglycerides.
[0213] The pharmaceutical composition may include a solubilizer to ensure good solubilization and / or dissolution of the compound and to minimize precipitation of the compound. This may be particularly useful for non-oral use, such as a pharmaceutical composition for injectable pharmaceutical compositions. A solubilizer may also be added to increase the solubility of hydrophilic drugs and / or other components such as surfactants, or to maintain the pharmaceutical composition as a stable or uniform solution or dispersion. Examples of suitable solubilizers include, but are not limited to, for example, alcohols and polyols such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediol and isomers thereof, glycerol, pentaerythritol sorbitol, mannitol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycol having a molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (tetrahydrofuran polyethylene glycol ether) or methoxy PEG; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, ε-caprolactam, N- -alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidine, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, esters, acetyl triethyl citrate, triethyl citrate, triethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and its isomers, δ-valine esters and its isomers, butyrolactone and its isomers; and other known solubilizers such as dimethylacetamide, dimethyl isosorbide, N-methylpyrrolidone, diethylene glycol monoethyl ether and water. Mixtures of solubilizers may also be used.
[0214] The amount of given solubilizing agent can be limited to biologically acceptable amount, and it can be easily determined by those skilled in the art.Based on the gross weight of medicine and other excipients, the weight ratio of solubilizing agent can be about 10 % by weight, about 25 % by weight, about 50 % by weight, about 100 % by weight or about 200 % by weight at the most.If desired, also can use a small amount of solubilizing agent, such as about 5%, 2%, 1% or less.Usually, solubilizing agent can be about 1 % by weight to about 100 % by weight, and usually about 5 % by weight to about 25 % by weight exist.
[0215] The pharmaceutical composition may also include one or more pharmaceutically acceptable additives and excipients, flavoring agents, coloring agents, suspending agents, adhesives, fillers, plasticizers, lubricants and mixtures thereof. Preservatives may include, but are not limited to, for example, antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acid preservatives and other preservatives. Antioxidants include, but are not limited to, alpha-tocopherol, ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium pyrosulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfate and sodium sulfite. Chelating agents include, but are not limited to, for example, ethylenediaminetetraacetic acid (EDTA), citrate monohydrate, disodium ethylenediaminetetraacetate, dipotassium ethylenediaminetetraacetate, ethylenediaminetetraacetic acid, fumaric acid, malic acid, phosphoric acid, sodium ethylenediaminetetraacetate, tartaric acid and triethylenediamine citrate tetraethyl ester. Antimicrobial preservatives include, but are not limited to, for example, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimonium bromide, cetylpyridinium chloride, chlorocresol, cresol, ethanol, glycerol, heptidine, imidazolidine, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate and propylene glycol. Antifungal agents include, but are not limited to, for example, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate and sorbic acid. Preservatives include, but are not limited to, for example, ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoic acid esters and phenylethyl alcohol. Acidic preservatives include, but are not limited to, for example, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid and phytic acid. Other preservatives include, but are not limited to, for example, tocopherol acetate, cetrimonium bromide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfate, sodium pyrosulfite, potassium sulfite, potassium pyrosulfite, methyl paraben. In certain embodiments, the preservative can be an antioxidant. In other embodiments, the preservative can be a chelating agent.
[0216] In some embodiments, provided herein are pharmaceutical compositions for parenteral administration: (1) an effective amount of a disclosed compound; optionally (2) an effective amount of one or more second agents; (3) one or more pharmaceutical excipients suitable for parenteral administration and (4) an effective amount of a third agent.
[0217] Wherein the pharmaceutical composition can be applied in the form of aqueous or oily suspension or emulsion, sesame oil, corn oil, cottonseed oil or peanut oil, as well as elixir, mannitol, glucose or sterile aqueous solution, similar pharmaceutical carrier. Saline solution is also commonly used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, benzyl alcohol, etc. (and their suitable mixtures), cyclodextrin derivatives, sodium chloride, tragacanth gum, buffer and vegetable oil can also be used. By using a coating, such as lecithin, or in the case of a dispersion, by using a surfactant to maintain the required particle size, appropriate fluidity can be maintained. The prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. The pharmaceutical composition can also be injected by a suitable carrier, including saline, glucose or water, or dissolved with cyclodextrin, cosolvent (e.g., propylene glycol) or micelle (e.g., Tween 80).
[0218] Sterile injectable solutions can be prepared by filtering and sterilizing with the desired amount of the compound disclosed herein and a suitable solvent for the various other ingredients mentioned above. Typically, dispersions are prepared by incorporating various sterilized active ingredients into a sterile carrier containing a basic dispersion medium and the appropriate other components listed above. Sterile injectable solutions are prepared with sterile powders, and some preparation methods are carried out by vacuum drying and freeze drying techniques to produce active ingredients and any other sterile filtered components mentioned above. The sterile injectable preparation can also be a solution (e.g., a solution of 1,3-butanediol) in a non-toxic parenteral acceptable diluent or solvent, or a sterile injectable solution. Acceptable carriers and solvents that can be used include, but are not limited to, for example, water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile non-volatile oils are typically used as solvents or suspension media, including but not limited to, for example, synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid can also be used to prepare injections. The injectable formulations can be sterilized, for example, by passing through a bacteria-retaining filter or by adding sterilizing agents incorporated into a sterile solid composition that can be dissolved or dispersed in sterile water or other sterile injectable medium. The injectable composition can be present in about 0.1% to about 5% by weight of the compound disclosed herein.
[0219] In some embodiments, provided herein are pharmaceutical preparations containing a compound (or transdermal) containing one or more pharmaceutical excipients, such as those disclosed herein that are suitable for topical administration. In some embodiments, provided are pharmaceutical compositions for topical administration containing: (1) an effective amount of a disclosed compound; optionally (2) an effective amount of one or more second agents; (3) one or more pharmaceutical excipients suitable for topical administration and (4) an effective amount of a third agent.
[0220] The pharmaceutical compositions provided herein can be formulated into solid, semisolid or liquid forms suitable for topical or local application, such as gelling agents, water-soluble gels, liniments, creams, lotions, suspensions, foams, powders, ointments, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, solutions based on dimethyl sulfoxide (DMSO). Typically, carriers with higher density can provide areas exposed to active ingredients for a long time. In contrast, solution formulations can provide more direct contact with areas selected by active ingredients. For example, ointment formulations can have paraffin or water miscibility. Alternatively, the active ingredient can be formulated as a cream with an oil-in-water cream base. The aqueous phase of the cream base can include, for example, at least about 30% by weight of a polyol, such as propylene glycol, 1,3-butylene glycol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The above-mentioned pharmaceutical compositions may also contain suitable solid or gel phase carriers or excipients, which can increase penetration or contribute to the delivery of compounds through the skin barrier layer of the stratum corneum. Examples include carbamides (e.g., urea), (e.g., menthol), amines, amides, alkanes, alkanols, water, such as isopropyl myristate and sodium sulfate, pyrrolidone, glyceryl monolaurate, sulfoxides, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
[0221] Another exemplary formulation used in the disclosed methods uses transdermal administration ("patch"). Such transdermal patches can be used to provide controlled or discontinuous pharmaceutical compositions in a continuous or discontinuous manner. If the active agent is absorbed by the skin, a controlled and predetermined flow of the active agent can be applied to the subject. In the case of microcapsules, the sealant can also be used as a membrane. The use of transdermal patches is well known in the art. See, for example, U.S. Patent Nos. 5,023,252, 4,992,445, and 5,001,139.
[0222] The pharmaceutical compositions of the present invention can be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients that are solid at room temperature but liquid at rectal temperature and will melt in the rectum to release the active ingredient. These materials include, but are not limited to, for example, polyethylene glycol, beeswax, and cocoa butter.
[0223] The pharmaceutical composition of the present invention can be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques known in the art of pharmaceutical preparation, can be prepared as saline solutions, and can be used with benzyl alcohol or other suitable preservatives to increase the bioavailability of absorption enhancers, fluorocarbons and other solubilizing or dispersing agents known in the art.
[0224] Application of the subject therapeutic agent can be localized for administration at a target site. A host composition can be provided at a target site using a variety of techniques, such as injection, use of a catheter, gel, stent, trocar, propellant, drug-releasing polymer or other device for providing internal access.
[0225] According to another embodiment, the invention provides an implantable medical device comprising a compound of the invention or a composition comprising a compound of the invention such that the compound is therapeutically active.
[0226] According to another embodiment, the invention provides a method of injecting an implantable drug delivery device, the method comprising the step of contacting the drug delivery device with a compound or composition of the present invention. Implantable drug delivery devices include but are not limited to biodegradable polymer capsules or pills, non-degradable dispersible polymer capsules and biodegradable polymer sheets.
[0227] In another embodiment, the composition of the present invention further comprises a second therapeutic agent. The second therapeutic agent includes any compound or therapeutic agent that is known to have or has advantageous properties when administered alone or in combination with any compound of the general formula herein. Drugs that can be effectively combined with these compounds include other kinase inhibitors and / or other chemotherapeutic agents for the treatment of the above-mentioned diseases and disorders. Such agents are described in detail in the art. Preferably, the second therapeutic agent is an agent that can be used to treat or prevent a disease or condition selected from cancer through a DNA double strand break mechanism.
[0228] In another embodiment, the present invention provides separate dosage forms of a compound of the present invention and a second therapeutic agent that are combined with each other. As used herein, the term "combined with each other" means that the separate dosage forms are packaged together or otherwise connected to each other so that the separate dosage forms are intended to be sold or administered together (within less than 24 hours, consecutively or simultaneously).
[0229] In the pharmaceutical composition of the present invention, the compound of the present invention is present in an effective amount. As used herein, the term "effective amount" refers to an amount sufficient to alleviate or improve the disorder to be treated, to prevent the progression of the disorder, to treat the interruption of the disorder, or to enhance or improve the severity, duration or development of the disorder of the preventive or therapeutic effect of another therapy when administered with a suitable dosing regimen.
[0230] The effective amount of the compounds of the present invention can be in the range of about 0.001 mg / kg to 1 mg / kg to about 500 mg / kg, about 0.01 mg / kg to about 50 mg / kg, about 0.1 mg / kg to about 2.5 mg / kg. As will be appreciated by those skilled in the art, the effective dose may also vary, depending on the disease being treated, the severity of the disease, the route of administration, the age, sex and general health of the patient, the use of excipients and other commonly used methods of treatment (e.g., the use of other agents) and the judgment of the treating physician.
[0231] For pharmaceutical compositions comprising a second therapeutic agent, an effective amount of the second therapeutic agent is about 20% to 100% of the dose normally used in a monotherapy regimen using only that agent. Preferably, the effective amount is about 70% to 100% of the normal monotherapy dose.
[0232] It is expected that some of the second therapeutic agents mentioned herein will act synergistically with the compounds of the present invention. When present, it will allow the effective dose of the second therapeutic agent and / or the compounds of the present invention to be less than the dose required for monotherapy. This has the following advantages, the side effects of the second therapeutic agent or compound of the present invention are minimized, the efficacy is improved, the ease of administration or use is improved, and / or the total cost of the compound preparation or formulation is reduced.
[0233] Treatment is as follows:
[0234] According to another embodiment, the present invention provides a method for treating a subject suffering from or susceptible to a disease or disorder or its symptoms (e.g., those described herein), the method comprising administering to the subject an effective amount of a compound of the present invention or a composition in one step. These diseases are well known in the art and are also disclosed herein.
[0235] Such treatment includes treatment of disorders mediated by protein kinases such as ATM.
[0236] In another aspect, the invention provides a method of treating a disease in a subject, the method comprising administering to the subject a composition comprising any of the compounds of the formulae herein.
[0237] In certain embodiments, the disease is mediated by ATM kinase.
[0238] In another embodiment, the disease is cancer or a proliferative disease.
[0239] In another embodiment, as inhibitors of activated ATM, the compounds of formula (I) and pharmaceutically acceptable salts are expected to be present in or partially mediated by the activity of ATM, such as the treatment of cancer or medical conditions. This can be used with the compounds of formula (I) or their pharmaceutically acceptable salts to treat cancer types including, but not limited to, ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, thymoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, gastric cancer, lung cancer, liver cancer, bone cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, bile duct cancer, endometrial cancer, renal cell carcinoma, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, melanoma, mesothelioma, brain cancer, adenocarcinoma, DIPG, skin cancer or head and neck squamous cell carcinoma.
[0240] In another embodiment, the disease is a cancer that is resistant to treatment with radiation.
[0241] In another embodiment, the disease is a cancer that is resistant to treatment with an agent that causes DNA double strand breaks.
[0242] In another embodiment, the disease is cancer with central nervous system metastases.
[0243] In another embodiment, the disease is glioma.
[0244] In another embodiment, the disease is glioblastoma.
[0245] In another embodiment, the disease is diffuse intrinsic pontine glioma.
[0246] In one embodiment, the method of the present invention is used to treat a subject suffering from or susceptible to a disease or condition. These diseases, disorders or their symptoms include, for example, those diseases, disorders or their symptoms regulated by protein kinases (e.g., ATM protein kinases). The disease or disease symptom can be, for example, cancer or a proliferative disease or disorder. The disease or disease symptom can be ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, diffuse endogenous pontine glioma, melanoma, prostate cancer, leukemia, lymphoma (GIST), thyroid cancer, bile duct cancer, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (GIST), gastric cancer, lung cancer, liver cancer, AML, multiple myeloma, melanoma, mesothelioma, brain cancer, membranous adenocarcinoma, skin cancer or head and neck squamous cell carcinoma. The methods described herein include those subjects wherein the subject is identified as the treatment that needs to be specifically described. Identification of a subject requiring treatment is within the judgment of the subject or a health care professional and can be subjective (eg, opinion) or objective (eg, measurable by a test or diagnostic method).
[0247] In another embodiment, the compounds of the general formula herein (and compositions thereof) can be used to treat diseases or disorders of subjects who have been treated with other therapeutic agents (e.g., anticancer agents, neurotrophic agents, psychotropic drugs, cardiovascular disease drugs, anti-obesity drugs, or diabetes drugs) and have developed resistance. On the one hand, the methods herein include administering compounds of the formula of those methods (or compositions thereof) to subjects in which the treatment is resistant (or identified as resistant to radiotherapy or chemotherapy treatment that causes DNA double-strand breaks). In other aspects, the subject is therefore responsive to treatment, so that the disorder is adjusted or improved before treatment with the compound of the formula of the present invention.
[0248] In another embodiment, the invention provides a method of modulating the activity of a protein kinase (eg, a protein kinase such as the kinases listed herein) in a cell, the method comprising contacting the cell with one or more compounds of the formulae herein.
[0249] The above anticancer treatments can be administered as monotherapy or together with conventional compounds or radiotherapy or chemotherapy or immunotherapy and the compounds of the present invention. Such chemotherapy may be co-administered simultaneously, sequentially or separately with the compounds of the invention, and may include, but is not limited to, one or more of the following classes of anti-tumor agents: for example, antiproliferative / antineoplastic agents, alkylating agents (e.g., cisplatin, oxaliplatin, carboplatin, cyclophosphamide, mechlorethamine, melphalan, chlorambucil, busulfan, temozolomide, and nitrosoureas), antimetabolites (e.g., gemcitabine and antifungal acids such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytarabine, and hydroxyurea); antitumor antibiotics (e.g., anthracyclines such as doxorubicin, bleomycin, adriamycin, daunorubicin, epirubicin, idarubicin, mitomycin C, gentamicin, and gliramycin); antimitotic agents (e.g., vinca alkaloids such as vincristine, alkaloids such as paclitaxel and tacrolimus, and polo kinase inhibitors); and topoisomerase inhibitors (e.g., epipodophyllotoxin I antagonists (e.g., goserelin, leuprolide and bucorin), progestins (e.g., megestrol acetate), aromatase inhibitors (e.g., anastrozole, letrozole, buoxazole and exemestane) and 5α-reductase inhibitors such as finasteride; anti-invasive agents (e.g., c-Src kinase family inhibitors such as ceritinib, dasatinib and bosutinib and bosutiphene), and metalloproteinase inhibitors such as equine protease inhibitors, urokinase plasminogen activator receptor inhibitors or antibody heparanase inhibitors. Inhibitors of growth factor function: For example, such inhibitors include growth factor antibodies and growth factor receptor antibodies (eg, the anti-erbB2 antibody trastuzumab [Herceptin TM], anti-EGFR antibody panitumumab, anti-ErbB antibody cetuximab (erbatide, C225) and Stem et al., "Critical reviews in oncology / haematology disclosed a growth factor receptor or a growth factor receptorantibody", 2005, Vol. 54, pp. 11-29. Such inhibitors also include tyrosine kinase inhibitors, such as epidermal growth factor family inhibitors (e.g., EGFR family inhibitors, such as gefitinib, erlotinib, icotinib, afatinib, dacomitinib and Tagrisso, erbB2 tyrosine kinase inhibitors, such as lapatinib, neratinib); hepatocyte growth factor family inhibitors; platelet-derived growth factor family, such as imatinib and / or nilotinib; serine / threonine kinase inhibitors (e.g., RAS / RAF signaling inhibitors, such as feniyltransferase inhibitors agents, such as sorafenib, tipifarnib and lonafarnib, MEK and / or AKT kinase cell signaling inhibitors, c-kit inhibitors, abl fusion kinase inhibitors, PI3 kinase inhibitors, PLT3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; Aurora kinase inhibitors and cyclin-dependent kinase inhibitors, such as CDK2 and / or CDK4 inhibitors; anti-angiogenic agents, such as those that inhibit the action of vascular endothelial growth factor; the antibody bevacizumab (Avastin TM) and, for example, VEGF receptor tyrosine kinase inhibitors, such as vandetanib, vatalanib, sunitinib, axitinib, cabozantinib, pazopanib and cediranib; compounds that act by other mechanisms (e.g., tricarboxyaminoquinolines, inhibitors of integrin αV3 function, and angiogenesis inhibitors); antisense (nucleic acid) therapy, including, for example, replacement of abnormal genes such as abnormal p53 or abnormal BRCA1 or BRCA2, as described above, such as ISIS2503, anti-ras gene antisense (nucleic acid) (e.g., olaparib, niraparib, rucaparib, tazopaliburib); GDEPT (gene-directed prodrug therapy) approaches, such as the use of enzymes of cytosine deaminase, thymidine kinase, or bacterial nitroreductase, and those that increase a patient's resistance to chemotherapy or radiation therapy Methods of reducing resistance to the method such as multidrug resistance gene therapy immunotherapy, including, for example, increasing the immunogenicity of the patient's tumor cells, for example, using cytokines such as interleukin 2, 4 or granulocyte-macrophage stimulating factor to transfect the immunogenicity of T cells to reduce the anergy of the method, using transfected immune cells such as cytokine-transfected dendritic cells, cytokine-transfected anti-idiotypic antibodies to reduce the function of immunosuppressive cells such as regulatory T cells, myeloid suppressor cells or IDO, TDO, and using antibodies derived from tumor-associated antigens such as NY-ES0-1, MAGE-3, WTI or HER2 / neu derived proteins or peptides or any other agents commonly used as a base or adjuvant in cancer treatment regimens (e.g., antiemetics, anti-anemic drugs, etc.).
[0250] As used herein, the term "co-administered" means that a second therapeutic agent can be combined with the compounds of the present invention in part as a single dosage form (e.g., a composition comprising a compound of the present invention and a second therapeutic agent as described above) or as an independent multiple dosage form. Alternatively, other agents may be administered before, in combination with, or after the administration of the compounds of the present invention. In such combination therapies, the compounds of the present invention and the second therapeutic agent are administered by conventional methods. Administration of the compositions of the present invention comprising the compounds of the present invention and the second therapeutic agent to a subject does not exclude administration of the same therapeutic agent, any other second therapeutic agent, or any compound of the present invention at other times during a course of treatment independently of administration to the subject. The continuous or separate administration or delayed administration of the second component should not lose the effect advantage resulting from the use of the combination.
[0251] In one embodiment of the invention, when a second therapeutic agent is administered to a subject, the effective amount of the compounds of the invention is lower than the effective amount of the second therapeutic agent when the second therapeutic agent is not administered. In another embodiment, the effective amount of the second therapeutic agent is less than the effective amount of the second therapeutic agent when the compounds of the invention are not administered. In this way, the undesirable side effects associated with any high dose of the agent can be minimized. Potential advantages are obvious to those skilled in the art (including, but not limited to, for example, improving dosing regimens and / or reducing drug costs).
[0252] In another aspect, the present invention provides the use of any compound of the general formula herein, alone or in combination with one or more second therapeutic agents as described herein, in the preparation of a medicament as a single composition or as a separate dosage form, for treating or preventing a disease, disorder or symptom listed herein in a subject. Another aspect of the present invention is the use of a compound of the general formula herein for treating or preventing a disease, disorder or symptom described herein in a subject.
[0253] In other aspects, the methods herein also include those methods for monitoring the subject's response to therapeutic administration. Such monitoring may include regular sampling of subject tissues, body fluids, cerebrospinal fluid, samples, cells, proteins, chemical markers, genetic material, etc., as markers or indicators of the treatment regimen. In other methods, the subject is pre-screened or identified as needing such treatment by assessing the suitability of the relevant markers or indicators to such treatment.
[0254] In one embodiment, the present invention provides a method for monitoring the progress of treatment. The method includes determining a diagnostic marker (marker) in a subject suffering from or susceptible to a disorder or symptom described herein (e.g., any target or cell type regulated by the compounds herein as described herein) or diagnosis (e.g., screening, determination), wherein the subject has been administered a therapeutic amount of a compound of the present invention sufficient to treat the disease or its symptoms. The marker level determined in the method can be compared with the known level in a healthy normal control or other sick patient to determine the disease condition of the subject. In a preferred embodiment, a second level of the marker in the subject is measured at a time point later than the first measured level, and the two levels are compared to monitor the progress of the disease or the efficacy of the treatment. In certain preferred embodiments, the marker level before treatment of the subject is measured before the start of treatment according to the present invention; the pre-treatment level of the marker can be the same as the level of the marker in the subject after the start of treatment to determine the effectiveness of the treatment.
[0255] In certain method embodiments, the level of a marker or marker activity in a subject is determined at least once. The marker level is compared with another measured value, for example, a measured value obtained previously or subsequently by the subject from the same patient, another patient or another subject, to determine whether the therapy according to the present invention has the desired effect, and therefore allows the dosage level to be adjusted as appropriate. The determination of the marker level can be carried out using any suitable sampling / expression assay method known in the art or described herein. Preferably, a tissue or liquid sample is first taken out from the subject. Examples of suitable samples include blood, urine, cerebrospinal fluid, tissue, oral or oral cells, and hair samples containing roots. Other suitable samples are well known to those skilled in the art. The determination of protein levels, ctDNA, cfDNA and / or mRNA levels (e.g., marker levels) in the sample can utilize any suitable technology known in the art, including but not limited to enzyme immunoassay, ELISA, radiolabeled technology, Western blotting / chemiluminescence, real-time PCR, electrochemical signals, etc.
[0256] The present invention also provides a kit for treating a disease, disorder or symptom described herein. Such a kit includes: 1) a pharmaceutical composition in a container, the pharmaceutical composition comprising any compound of the general formula herein or a salt thereof; or a salt thereof; or a pharmaceutical composition of a hydrate, solvate or polymorph thereof; and 2) instructions describing the use of the pharmaceutical composition for treating a method including a disease, disorder or symptom described herein. The container can be any container or other sealed or sealable device capable of containing a pharmaceutical composition. Examples include bottles, individual or multi-chamber storage bottles, wherein each partition or compartment contains a single dose of the composition; separate foil packages, wherein each partition contains a single dose of the composition, which distributes a single dose of the composition. The container can be any conventional shape or form known in the art and made of pharmaceutically acceptable materials, such as paper or cardboard boxes, glass or plastic bottles or cans, resealable bags (e.g., "refills" of tablets for placement in different containers), or using single-dose blister packaging to squeeze the package out of the treatment regimen. The container used may depend on the exact dosage form involved, for example, conventional cardboard boxes are not generally used to hold liquid suspensions. More than one container may be used together in a single package to sell a single dosage form. For example, tablets may be packaged in a bottle, which is then contained in a box. Preferably, the container is a blister pack.
[0257] The kit may additionally include information and / or instructions from a physician, pharmacist or subject. These memory aids include numbers printed on each compartment or partition containing the medicament, which numbers correspond to the days of the program or capsule that should be ingested, or the days of the week printed on each compartment or partition, or cards containing the same type of information.
[0258] The compounds described herein can be evaluated using known protocols thereof, including, for example, those described herein, to evaluate their biological activity. Some of the compounds herein exhibit surprisingly excellent properties (e.g., metabolic stability, high selectivity, low efflux rate, high permeability, non-P-glycoprotein and BCRP efflux substrates, non-aldehyde oxidase substrates, low hERG tendency, low drug-drug interaction tendency, etc.), making them excellent potential therapeutic agent candidates.
[0259] All references cited herein, whether in electronic, printed, computer-readable or other form, are expressly incorporated by reference in their entirety, including but not limited to abstracts, articles, journals, publications, textbooks, treatises, technical data sheets, internet websites, databases, patents, patent applications, and patent publications.
[0260] The present invention will now be described in detail with reference to the following examples. The following examples will help those skilled in the art to further understand the present invention, and do not limit the present invention in any way. It should be noted that those skilled in the art can make many modifications and improvements without departing from the spirit of the present invention. All these modifications and improvements are within the scope of the present invention.
[0261] Example 1
[0262] Intermediates 3,3-difluoro-1-methylpiperidin-4-amine A6 and 1-benzyl-3,3-difluoropiperidin-4-amine A5' are as follows Figure 2 Synthesis shown.
[0263] Step 1: To a solution of 2-methylpropane-2-sulfinamide (404 g, 3.33 mol) and Ti(OEt)4 (1003 g, 4.44 mol) in THF (2.5 L) at 25°C was added a solution of A1 (500 g, 2.22 mol) dropwise. The reaction mixture was stirred at 70°C for 1 hour and then cooled to 0°C. The reaction mixture was then added to a solution of NaBH4 (166 g, 2.0 equiv) in THF (2.5 L) in another reactor at 0°C. The reaction mixture was stirred at 0°C for 0.5 hour, then slowly warmed to 25°C and continued to stir for 0.5 hour. Methanol (2.5 L) was added and then stirred for 0.5 hour. The mixture was added to a container containing a saturated solution of NaCl (2.5 L) and stirred at 25°C for 1 hour. The reaction mixture was extracted twice with DCM (2.5 L). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to give the product A2.
[0264] Step 2: To a solution of crude A2 in ethyl acetate (1 L) was added HCl (5.0 eq., 4 M solution in ethyl acetate) at 25 °C, stirred at 25 °C for 1 hour, and then filtered to afford A3.
[0265] Step 3: Water (1.5 L) was added to the filter cake A3, and then the pH was adjusted to 8-9 with a 20% NaOH aqueous solution at 25°C. The mixture was extracted with DCM (1.5 L), and the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. Triethylamine (267 g, 1.2 eq) was added to the crude product, followed by (Boc)2O (577 g, 1.2 eq), and the mixture was stirred at 25°C for 1 hour. 10% citric acid solution (2 L) was added to the mixture, and the organic layer was separated. The aqueous layer was extracted with DCM (1 L). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to give A4 (430 g, 59.4%).
[0266] Step 4: Pd(OH)2 / C (20%, w / w) was added to a solution of A2 (380 g, 1.0 eq.) in MeOH (3.8 L), and the mixture was stirred at 25°C and 20 atm for at least 1 hour. The mixture was filtered and the filtrate was concentrated to give A5 (250 g, 91%).
[0267] Step 4': A mixture of A4 (4 g, 12.27 mmol) in TFA (20 mL) was stirred at room temperature for 2 hours. The mixture was concentrated in vacuo. The residue was further purified by column chromatography (DCM:MeOH=12:1) to give compound A5' (2 g, 74.1%) as a yellow oil.
[0268] Step 5: To a solution of A5 (236 g, 1.0 eq.) in MeOH (2.4 L) was added HCHO (37% aqueous solution, w / w) at 5°C. The reaction mixture was stirred at 5°C for 1 hour, then NaBH(OAc)3 was added in portions until LC-MS indicated the disappearance of A5. A 10% aqueous NaOH solution was added to the reaction mixture at 25°C to adjust the pH to 8-9, and stirred at 25°C for 0.5 hour. Methanol was evaporated in vacuo, and the residue was extracted with ethyl acetate (1.2 L). The organic layer was separated and concentrated. HCl (5.0 eq., 4 M ethyl acetate solution) was added, then filtered. The filter cake was collected and dried in vacuo at 45°C to give the HCl salt of A6 (125.1 g, 53.7%).
[0269] Intermediates 8-bromo-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one B5 and 8-bromo-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-(deuterated methyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one B5′ are prepared as follows: Figure 3 Synthesis shown.
[0270] Step 1: To a mixture of B1 (25 g, 79.48 mmol) in DMA (500 mL) was added A6 (14.92 g, 99.34 mmol) and DIEA (30 g, 238.744 mmol). The mixture was heated to 60 ° C for 5 hours. The mixture was cooled to room temperature and poured into a mixture of DCM (500 mL) and H2O (250 mL). The organic layer was separated and washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give B2 (15 g, 44.09%) as an off-white solid. LC-MS: (ESI) m / z=404 [M+H] +
[0271] Step 2: At room temperature, NaOH (8 g, 100 mmol) was added to a mixture of B2 (15 g, 33.35 mmol) in MeOH / H2O / THF (300 mL / 150 mL / 150 mL) and heated to 50° C. for 2 hours. The mixture was cooled to room temperature and the organic layer was removed by vacuum concentration. The residue was added to H2O (150 mL), adjusted to pH=4 by adding 10% HCl, and filtered to give B3 (11 g, 78.57%) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ12-11.85(m,1H),8.80-8.65(m,1H),8.01-7.67(m,2H),5.35-5.01(m,1H),3.68-3.51(m,1H),3. 30-3.22(m,1H),3.17(d,J=8.0Hz,1H),2.92(d,J=12.0Hz,1H),2.63-2.53(m,1H),2.47-2.29(m,4H),2.07-1.92(m,1H).
[0272] Step 3: To a solution of B3 (11 g, 27.5 mmol) and DPPA (7.12 mL, 33 mmol) in DMF (350 mL) was added TEA (28.2 mL, 82.5 mmol). The mixture was stirred at 60 °C for 2 hours. The reaction was cooled to room temperature and then poured into H2O (500 mL). The precipitate was filtered, washed with H2O (50 mL), and the filter cake was dried to give B4 (10 g, 91.82%) as a brown solid.
[0273] Step 4: To a mixture of B4 (10 g, 25.2 mmol) in DMF (250 mL) was added DMF-DMA (15.15 g, 126 mmol) at room temperature. The mixture was then heated to 80°C for 2 hours, cooled to room temperature, and filtered. The filtrate was washed with H2O and dried to give B5 (9 g, 86.95%) as an off-white solid. 1 H NMR(400MHz,DMSO-d6)δ9.05-8.95(m,1H),8.75–8.36(m,1H),8.04-7.71(m,2H),5.37-5.16(m,1H),3.67-3.55(m,1H),3.50(s,2H) ,3.30-3.23(m,1H),2.93(d,J=8.0Hz,1H),2.74-2.53(m,1H),2.48-2.32(m,4H),2.07-1.93(m,1H).LC-MS: (ESI)m / z=411,413[M+H] +
[0274] Step 4': A solution of B4 (400 mg, 1.01 mmol) in THF (20 mL) was cooled at -78 ° C, NaHMDS (221 mg, 1.21 mmol, 1 M THF solution) was added to the mixture and stirred at -78 ° C for 30 minutes. CD3I (87 mg, 1.21 mmol) was then added dropwise to the mixture. The reaction mixture was stirred at room temperature for 16 hours. H2O (10 mL) was added to the mixture, extracted with EtOAc (30 mL×3), and the organic layer was then washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (DCM: MeOH = 30: 1) to give compound B5' (380 mg, 91.9%) as a yellow solid. LC-MS: (ESI) m / z = 414,416 [M+H] +
[0275] Intermediate 8-bromo-1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one C5 Figure 4 Synthesis shown.
[0276] Step 1: To a mixture of C1 (1.48 g, 4.45 mmol) in DMA (20 mL) was added A6 (1.09 g, 9.54 mmol) and DIEA (1.72 g, 13.35 mmol). The mixture was heated to 80 °C for 8 hours. The mixture was cooled to room temperature and poured into a mixture of ethyl acetate (200 mL) and H2O (100 mL). The organic layer was separated and washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to afford C2 (2.2 g, 100%) as a brown solid. LC-MS: (ESI) m / z=448 [M+H] +
[0277] Step 2: To a mixture of C2 (2.2 g, 5 mmol) in MeOH / H2O / THF (60 mL / 20 mL / 20 mL) was added NaOH (1 g, 25 mmol) at room temperature and heated to 60°C for 2 hours. The mixture was cooled to room temperature and concentrated in vacuo to remove the organic layer. The residue was added to H2O (50 mL), adjusted to pH = 4 by adding 10% HCl, and filtered to give C3 (2 g, 92.4%) as a yellow solid. LC-MS: (ESI) m / z = 420 [M+H] +
[0278] Step 3: TEA (1.4 g, 13.86 mmol) was added to a solution of C3 (1.93 g, 4.62 mmol) and DPPA (1.53 g, 5.55 mmol) in DMF (10 mL). The mixture was stirred at 60 ° C for 2 hours. The reactant was cooled to room temperature and then poured into H2O (80 mL) and extracted with ethyl acetate (200 mL). The organic layer was separated and washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography to give C4 (1.19 g, 61.7%) as a brown solid. 1 HNMR (400MHz, CD3OD_SPE) δ9.04–8.73(m,1H),8.69(d,J=2.7Hz,1H),8.54(d,J=6.6Hz,1H),7.80(dd,J=9.7,2.9Hz,1H),5.20(dd,J=23.7,8.8 Hz,1H),3.80(d,J=12.1Hz,1H),3.21–2.83(m,2H),2.66(dd,J=28.4,12.5Hz,1H),2.54–2.41(m,4H),2.07(s,1H).LC-MS: (ESI)m / z=417[M+H] +
[0279] Step 4: Methyl iodide (334 mg, 2.42 mmol) was added to a mixture of C4 (500 mg, 1.21 mmol), NaOH (73 mg, 1.82 mmol) and TBAHS (41 mg, 0.12 mmol) in DCM / H2O (4 mL / 3 mL). The resulting mixture was stirred at room temperature for 5 hours. The cooled mixture was poured into a mixture of DCM (200 mL) and H2O (150 mL). The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by Pre-TLC to give C5 (533 mg, 100%) as a brown solid. 1 H NMR (400MHz, DMSO) δ9.09–8.95(m,1H),8.89–8.53(m,1H),8.03–7.96(m,1H),5.31(dd,J=25.6,11.6Hz,1H),3.73–3.60(m,1H),3. 54(d,J=34.3Hz,3H),3.28–3.12(m,3H),2.71–2.54(m,2H),2.48–2.29(m,4H),1.98(d,J=12.5Hz,1H).LC-MS: (ESI)m / z=431[M+H] +
[0280] Intermediate 1-(3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one D7 Figure 5 Synthesis shown.
[0281] Step 1: A mixture of B1 (5 g, 15.90 mmol), A5' (4.32 g, 19.07 mmol) and DIEA (3.54 g, 38.14 mmol) in DMA (50 mL) was heated to 100 ° C for 12 hours. The mixture was poured into H2O (100 mL), extracted with EtOAc (100 mL×3), and then the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (DCM: MeOH = 30: 1) to give compound D2' (3 g, 37.42%) as a yellow oil.
[0282] Step 2: To a mixture of D2 (2.3 g, 4.56 mmol) in MeOH / H2O / THF (20 mL / 5 mL / 5 mL) was added NaOH (0.65 g, 16.2 mmol) at room temperature and heated to 50°C for 2 hours. The mixture was cooled to room temperature, concentrated in vacuo to remove the organic layer, and the residue was added to H2O (50 mL), adjusted to pH = 4 by adding 10% HCl aqueous solution, and filtered to give D3 (2.0 g, 92.08%) as an off-white solid. LC-MS: (ESI) m / z = 506.0 [M+H].
[0283] Step 3: A solution of D3 (2.0 g, 4.20 mmol), DPPA (1.7 g, 6.18 mmol), TEA (3.74 g, 25.1 mmol) in DMF (35 mL) was stirred at 60 ° C for 2 hours. The reaction mixture was cooled to room temperature. The mixture was poured into H2O (50 mL) and the precipitate was filtered. The solid was washed once with H2O and the filter cake was dried to give D4 (1.8 g, 90.57%) as a brown solid.
[0284] Step 4: To a mixture of D4 (1.80 g, 3.80 mmol) in DMF (25 mL) was added DMF-DMA (2.30 g, 19.2 mmol) at room temperature. The mixture was then heated to 80 °C for 2 hours. The reaction mixture was cooled to room temperature and then filtered. The filter cake was washed with H2O and dried to give D5 (1.0 g, 53.96%) as an off-white solid. LC-MS: (ESI) m / z=489.2 [M+H].
[0285] Step 5: A mixture of D5 (1.0 g, 2.05 mmol), (6-methoxypyridin-3-yl)boronic acid (377 mg, 2.46 mmol), PdCl2(dtdppf) (240 mg, 0.21 mmol), K2CO3 (1.5 mg, 6.15 mmol) in 1,4-dioxane / H2O (15 mL / 4 mL) was degassed twice with N2 and then heated to 80°C for 3 hours. The reaction mixture was poured into a mixture of DCM (50 mL) and H2O (50 mL), and the organic layer was then washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (DCM:MeOH=30:1) to give compound D6 (1 g, 94.53%) as a white solid. 1HNMR(400MHz,DMSO)δ8.95(d,J=32.8Hz,1H),8.80(s,1H),8.67(s,J=43.2,2.4Hz,1H),8.37(s,1H),8.23–8.0 9(m,2H),8.00–7.90(m,1H),7.40–7.23(m,5H),7.01(d,J=8.6Hz,1H),5.59–5.23(m,1H),3.98–3.90(m,3H),3. 79(d,J=13.3Hz,1H),3.73(m,J=11.2,4.4Hz,2H),3.58(m,J=32.0,21.2Hz,4H),3.11(d,J=11.0Hz,1H),3.03–2 .87(m,1H),2.74–2.55(m,1H),2.40(m,J=32.4,18.1Hz,1H),2.07–1.94(m,1H).LC-MS: (ESI)m / z=516.0[M+H].
[0286] Step 6: Pd(OH)2 / C (100 mg, 10% Pd, water <10%) was added to a solution of D6 (400 mg, 0.78 mmol) in MeOH (10 mL). The reaction mixture was stirred at 30°C for 5 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give compound D7 (300 mg, 90.89%) as a brown oil. LC-MS: (ESI) m / z = 426.0 [M+H].
[0287] Intermediate 2-cyclopropyloxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine E3 Figure 6 Synthesis shown.
[0288] Step 1: A mixture of E1 (1 g, 5.68 mmol), cyclopropanol (396 mg, 6.82 mmol) and KOtBu (2.1 g, 14.3 mmol) in THF (20 mL) was heated to 80 ° C for 3 hours. H2O (40 mL) was added to the mixture, extracted with EtOAc (40 mL×3), and then the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether: EtOAc = 4: 1) to give compound E2 (1.1 g, 90.4%) as a yellow oil.
[0289] Step 2: A mixture of E2 (1.1 g, 5.14 mmol), Pin2B2 (1.57 g, 6.17 mmol) and KOAc (1.5 g, 15.42 mmol) in dioxane (20 mL) was heated to 100 ° C for 8 hours. H2O (40 mL) was added to the mixture, extracted with EtOAc (40 mL×3), and then the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether: EtOAc = 4: 1) to give compound E3 (700 mg, 52.23%) as a yellow oil.
[0290] Intermediate 2-(deuterated methoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine F3 Figure 7 Synthesis shown.
[0291] Step 1: A mixture of F1 (1 g, 5.75 mmol) and AgCO (3.17 mg, 11.49 mmol) in CHCl (15 mL) was stirred at 30° C. for 3 hours. The mixture was poured into a mixture of DCM (30 mL) and H0 (30 mL), and the organic layer was washed with brine, dried over anhydrous NaSO, filtered and concentrated in vacuo to give compound F2 (900 mg, 81.97%) as a colorless oil.
[0292] Step 2: A mixture of F2 (900 mg, 4.71 mmol), Pin2B2 (1.44 g, 5.65 mmol) and KOAc (1.38 g, 14.51 mmol) in dioxane (20 mL) was heated to 100 ° C for 8 hours. H2O (40 mL) was added to the mixture, extracted with EtOAc (40 mL×3), and then the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether: EtOAc = 4: 1) to give compound F3 (800 mg, 71.3%) as a yellow oil.
[0293] Intermediate N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine G2 Figure 8 Synthesis shown.
[0294] A mixture of G1 (550 mg, 2.74 mmol) and Pin2B2 (835 mg, 3.288 mmol) in dioxane (20 mL) was added Pd(dppf)Cl2 (201 mg, 0.274 mmol) and KOAc (807 mg, 8.22 mmol), and the mixture was stirred at 100°C for 3 hours. The mixture was cooled to room temperature, filtered, concentrated in vacuo, and purified by silica gel column chromatography (DCM: MeOH = 10: 1) to give G2 (300 mg, 44.1%). LC-MS: (ESI) m / z = 248, 249 [M+H] +
[0295] Intermediate N,N-dimethyl-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)azetidine-3-amine H2 Fig. 9 Synthesis shown.
[0296] Step 1: To a mixture of E1 (550 mg, 3.1 mmol) and N,N-dimethylazetidine-3-amine hydrochloride (805 mg, 4.65 mmol) in DMF (5 mL) was added DIEA (2003 mg, 15.5 mmol), and the mixture was stirred at 90 ° C for 12 hours. The mixture was cooled to room temperature, poured into water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4, concentrated in vacuo, and purified by silica gel column chromatography (DCM: MeOH = 10: 1) to give H1 (438 mg, 55%). LC-MS: (ESI) m / z = 257,258 [M + H] +
[0297] Step 2: To a mixture of H1 (438 mg, 1.71 mmol) and Pin2B2 (521 mg, 2.05 mmol) in dioxane (20 mL) was added Pd(dppf)Cl2 (125 mg, 0.171 mmol) and KOAc (503 mg, 5.13 mmol), and the mixture was stirred at 100 ° C for 3 hours. The mixture was cooled to room temperature, filtered, concentrated in vacuo, and purified by silica gel column chromatography (DCM: MeOH = 10: 1) to give H2 (359 mg, 63.6%). LC-MS: (ESI) m / z = 303,304 [M + H] +
[0298] Intermediate 2-methyl-6-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-2,6-diazabicyclo[3.2.0]heptane I6 Fig.10 Synthesis shown.
[0299] Step 1: To a mixture of I1 (50 mg, 0.174 mmol) in THF (5 mL) was added Pd / C (10 mg, 0.08 mmol). The mixture was heated to 50 °C under H2 for 12 h. The mixture was filtered and the filtrate was concentrated in vacuo to give I2 (30 mg, 90%) as an off-white solid. LC-MS: (ESI) m / z = 198.9 [M+H] +
[0300] Step 2: To a mixture of I2 (30 mg, 0.152 mmol) in DMSO (3 mL) was added E1 (40 mg, 0.5 mmol) and DIEA (28 mg, 0.3 mmol) at room temperature and heated to 120° C. for 2 hours. The reaction was cooled to room temperature and then poured into H2O (50 mL), the organic layer was washed with brine, dried over anhydrous Na2SO4, and purified by column (DCM: MeOH = 30: 1) to give I3 (33 mg, 78.57%) as an off-white solid.
[0301] Step 3: TFA (19 mg, 0.27 mmol) was added to a solution of I3 (33 mg, 0.093 mmol) in DCM (3 mL). The mixture was stirred at room temperature for 1 hour. The mixture was poured into a mixture of DCM (15 mL) and H2O (15 mL), and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column (DCM: MeOH = 30: 1) to give I4 (20 mg, 91.82%) as a brown solid.
[0302] Step 4: Under N2, NaBH3CN (13 mg, 0.16 mmol) and CH2O aqueous solution were added to a solution of I4 (20 mg, 0.079 mmol) in AcOH (2 mL) and MeCN (2 mL). The mixture was stirred at room temperature for 1 hour. The mixture was poured into a mixture of DCM (15 mL) and H2O (15 mL), and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column (DCM: MeOH = 30: 1) to give I5 (12 mg, 91.82%) as an off-white solid.
[0303] Step 5: A mixture of I5 (12 mg, 0.045 mmol), Pin2B2 (20 mg, 0.13 mmol), PdCl2(dppf) (3 mg, 0.004 mmol) and AcOH (6 mg, 0.08 mmol) in 1,4-dioxane (3 mL) was degassed twice with N2 and then heated to 100°C for 3 hours. The mixture was poured into a mixture of DCM (15 mL) and H2O (15 mL), and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column (DCM:MeOH=30:1) to give I6 (15 mg, 56.07%) as a white solid.
[0304] General methods for coupling boronate intermediates with aryl bromides are as follows Fig.11 shown.
[0305] The mixture of starting material (1 equivalent), boronate intermediate (1.2 equivalents), PdCl2(dtdppf) (1 equivalent), K2CO3 (3 equivalents) in 1,4-dioxane / H2O (2.5:1, v / v, 0.035M) was degassed twice with N2 and then heated to 80°C for 3 hours. The mixture was poured into a mixture of DCM and H2O, the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column (DCM: MeOH = 30: 1) to give the desired coupling product.
[0306] Representative examples of the general method for coupling boronate intermediates with aryl bromides are shown in Fig.12 shown.
[0307] A mixture of B5 (2 g, 4.87 mmol), pyridin-3-ylboronic acid (888 mg, 5.844 mmol), PdCl2(dtdppf) (318 mg, 4.87 mmol), K2CO3 (2 g, 14.61 mmol) in 1,4-dioxane / H2O (100 mL / 40 mL) was degassed twice with N2 and then heated to 80°C for 3 hours. The mixture was poured into a mixture of DCM (500 mL) and H2O (500 mL), the organic layer was washed with brine, dried over anhydrous Na2SO4, and purified by column chromatography (DCM:MeOH=30:1) to give the product (1.22 g, 57.07%) as a white solid. 1H NMR(400MHz, DMSO)δ9.09(d,J=42.0,1.9Hz,1H),8.98(d,J=26.8Hz,1H),8.90(s,1H),8.67–8.61(m,1H),8.48 (s,1H),8.34–8.19(m,1H),8.18(d,J=8.8Hz,1H),8.15-8.05(m,1H),7.68-7.48(m,1H),5.57–5.25(m,1H),3.6 9(d,J=4.0Hz,1H),3.56(d,J=33.2Hz,3H),3.44–3.34(m,1H),3.30(s,1H),3.11(d,J=11.2Hz,1H),2.94(d,J= 12.0Hz,1H),2.73-2.53(m,1H),2.42(d,J=32.4,16.4Hz,4H),2.11–1.92(m,1H).LC-MS:(ESI)m / z=410.1[M+H] +
[0308] The general method for chiral separation of racemic products 1-13 is as follows Fig.13 shown.
[0309] The sample was dissolved in about 150 mL of EtOH and quenched using a chiral preparative SFC column (Waters SFC 150, 250*25 mm 10 μm AS SFC column) was injected once every 7 mL to separate the enantiomers (55:45 supercritical CO2:EtOH mobile phase, flow rate of 70 g / min, monitoring wavelength of 214 nm).
[0310] Representative examples of general methods for chiral separation of racemic products are shown in Fig.14 shown.
[0311] According to the general method for chiral separation of racemic products, (R)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (500 mg, 99% yellow solid) was obtained from 1.22 g of 1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. 1H NMR(400MHz, DMSO)δ9.09(d,J=42.0,1.9Hz,1H),8.98(d,J=26.8Hz,1H),8.90(s,1H),8.67–8.61(m,1H ),8.48(s,1H),8.34–8.19(m,1H),8.18(d,J=8.8Hz,1H),8.15-8.05(m,1H),7.68-7.48(m,1H),5.57–5 .25(m,1H),3.69(d,J=4.0Hz,1H),3.56(d,J=33.2Hz,3H),3.44–3.34(m,1H),3.30(s,1H),3.11(d,J=1 1.2Hz,1H),2.94(d,J=12.0Hz,1H),2.73-2.53(m,1H),2.42(d,J=32.4,16.4Hz,4H),2.11–1.92(m,1H). LC-MS: (ESI) m / z=410.1 [M+H] SFC: 99% and (S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one (504 mg, 99.03% yellow solid), 1 HNMR(400MHz,DMSO)δ9.09(d,J=42.0,1.9Hz,1H),8.98(d,J=26.8Hz,1H),8.90(s,1H),8.67–8.60(m,1 H),8.48(s,1H),8.34–8.19(m,1H),8.18(d,J=8.8Hz,1H),8.15-8.05(m,1H),7.68-7.48(m,1H),5.57– 5.24(m,1H),3.71–3.62(m,1H),3.56(d,J=33.2Hz,3H),3.44–3.34(m,1H),3.30(s,1H),3.10(d,J=11. 2Hz,1H),2.94(d,J=12.0Hz,1H),2.73-2.53(m,1H),2.42(dd,J=32.4,16.4Hz,4H),2.11–1.93(m,1H). LC-MS: (ESI) m / z=410.1 [M+H] SFC: 99%.
[0312] Example 2
[0313] The synthesis of compound 1 is as follows Fig.15Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0314] Following the general procedure for coupling boronic ester intermediates with aryl bromides, compound 1 (1.2 g, 56.07%) was obtained as a white solid from a mixture of B5 (2 g, 4.87 mmol), (6-methoxypyridin-3-yl)boronic acid (888 mg, 5.844 mmol), PdCl2(dtdppf) (318 mg, 4.87 mmol) and K2CO3 (2 g, 14.61 mmol) in 1,4-dioxane / H2O (100 mL / 40 mL). 1 H NMR (400MHz, DMSO) δ8.94(d,J=25.6Hz,1H),8.80(s,1H),8.68(dd,J=39.6,2.0Hz,1H),8.38(s,1H ),8.29–8.10(m,2H),8.05-7.95(m,1H),7.01(dd,J=18.8,8.8Hz,1H),5.45-5.25(m,1H),3.94(d, J=4.8Hz,3H),3.73–3.61(m,1H),3.56(d,J=33.2Hz,3H),3.44–3.35(m,1H),3.15–2.87(m,1H),2. 72–2.53(m,1H),2.48–2.39(m,2H),2.35(s,2H),2.10–1.91(m,1H).LC-MS: (ESI)m / z=440.1[M+H] +
[0315] Example 3
[0316] The synthesis of compound 2 is as follows Fig.16 Shown: Synthesis of (R / S)-1-(1-ethyl-3,3-difluoropiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0317] To a mixture of D7 (100 mg, 0.24 mmol) in acetaldehyde (10 mL) was added NaBH3CN (18 mg, 0.28 mmol). The mixture was stirred at 30 ° C for 5 hours. H2O (20 mL) was added to the mixture, extracted with EtOAc (20 mL×3), and then the organic layer was concentrated in vacuo. The residue was purified by column chromatography (DCM: MeOH = 30: 1) to give compound 2 (10 mg, 9.38%) as a white solid. LC-MS: (ESI) m / z = 454.0 [M+H]. 1 H NMR(400MHz,DMSO-d6)δ8.99–8.89(m,1H),8.80(s,0.4H),8.75–8.61(m,1H),8.39(s,0.5H),8.25–8 .11(m,2H),8.04–7.91(m,1H),7.05–6.90(m,1H),5.55–5.24(m,1H),3.93(d,J=8.0Hz,3H),3.70–3. 62(m,0.3H),3.60(s,1H),3.52(s,2H),3.49–3.35(m,1H),3.20(d,J=8.0Hz,0.7H),3.04(d,J=8.0Hz ,1H),2.66–2.59(m,1H),2.58–2.53(m,1H),2.46–2.38(m,2H),2.10–1.93(m,1H),1.16–1.04(m,3H).
[0318] Example 4
[0319] The synthesis of compound 3 is as follows Fig.17 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-isopropylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0320] NaBH3CN (22 mg, 0.35 mmol) was added to a solution of D7 (100 mg, 0.24 mmol) in propan-2-one (10 mL). The reaction mixture was stirred at 30 ° C for 5 hours. H2O (20 mL) was added to the mixture, extracted with EtOAc (20 mL×3), and then the organic layer was concentrated. The residue was purified by column chromatography (DCM: MeOH = 30: 1) to give compound 3 (10 mg, 9.74%) as a white solid. LC-MS: (ESI) m / z = 468.2 [M+H]. 1H NMR (400MHz, DMSO-d6) δ8.99–8.89(m,1H),8.80(s,0.5H),8.73–8.60(m,1H),8.39(s,0.5H),8.22–8.09(m,2H),8.02-7.90(m,1H),7. 04-6.89(m,1H),5.52–5.19(m,1H),3.95–3.88(m,3H),3.61–3.35(m,4H),3.15–2.53(m,5H),2.09–1.93(m,1H),1.05(d,J=8.0Hz,6H).
[0321] Example 5
[0322] The synthesis of compound 4 is as follows Fig.18 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-ethoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0323] Following the general procedure for coupling boronic acid ester intermediates with aryl bromides, compound 4 (1.3 g, 59.1%) was obtained as a white solid from a mixture of B5 (2 g, 4.87 mmol), (6-ethoxypyridin-3-yl)boronic acid (970 mg, 5.844 mmol), PdCl2(dtdppf) (318 mg, 0.49 mmol) and K2CO3 (2 g, 14.61 mmol) in 1,4-dioxane / H2O (100 mL / 40 mL). LC-MS: (ESI) m / z=454.1 [M+H] + , 1 H NMR(400MHz,DMSO-d6)δ9.03-8.95(m,1H),8.79(s,0.35H),δ8.74-8.53(m,1H),δ8.44 -8.33(m,1H),8.30-8.06(m,2H),8.05-7.85(m,1H),7.05–6.96(m,1H),5.58-5.20(m, 1H),4.39(s,2H),3.74–3.62(m,0.57H),3.62–3.42(m,3H),3.45–3.36(m,0.47H),3.1 7–2.93(m,2H),2.74–2.56(m,1H),2.49–2.29(m,4H),2.13–1.96(m,1H),1.36(s,3H).
[0324] Example 6
[0325] The synthesis of compound 5 is as follows Fig.19 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-7-fluoro-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0326] Following the general procedure for coupling boronic acid ester intermediates with aryl bromides, a mixture of C5 (150 mg, 0.35 mmol), (6-methoxypyridin-3-yl)boronic acid (70 mg, 0.46 mmol), PdCl2(dtdppf) (14 mg, 0.02 mmol), K2CO3 (145 mg, 1.05 mmol) in 1,4-dioxane / H2O (4 mL / 0.8 mL) was degassed twice with N2 and then heated to 90°C for 3 hours. The mixture was poured into H2O (20 mL), extracted with DCM (45 mL), and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by Pre-HPLC (FA) to give compound 5 (79.2 mg, 49.4%) as a white solid. 1 H NMR(400MHz,DMSO)δ8.98(d,J=27.3Hz,1H),8.72(d,J=8.0Hz,1H),8.63–8.13(m ,2H),8.17–7.95(m,1H),7.93(d,J=12.2Hz,1H),7.11–6.86(m,1H),5.49–5.24( m,1H),3.94(d,J=5.6Hz,3H),3.68–3.35(m,4H),3.08(d,J=10.8Hz,1H),2.99–2 .57(m,2H),2.48–2.17(m,4H),2.08–1.79(m,1H).LC-MS: (ESI)m / z=458.3[M+H] +
[0327] Example 7
[0328] The synthesis of compound 6 is as follows Fig. 20 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-(deuterated methyl)piperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0329] A solution of D7 (100 mg, 0.24 mmol) in ACN (20 mL) was stirred at 28 ° C, K2CO3 (71.4 mg, 0.52 mmol) was added to the mixture and stirred at 28 ° C for 30 minutes. CD3I (51 mg, 0.35 mmol) was then added dropwise to the reaction mixture. The mixture was stirred at room temperature for 16 hours. H2O (10 mL) was added to the reaction mixture, extracted with EtOAc (30 mL×3), and the organic layer was then washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (DCM: MeOH = 30: 1) to give compound 6 (2.6 mg, 2.5%) as a white solid. LC-MS: (ESI) m / z = 442.2 [M+H]. 1 H NMR(400MHz,DMSO-d6)δ8.99–8.89(m,1H),8.80(s,0.3H),8.75–8.61(m,1H),8.38(s,0.7H), 8.25–8.11(m,2H),8.05–7.91(m,1H),7.05–6.95(m,1H),5.55–5.24(m,1H),3.94(d,J=4.0Hz, 3H),3.70–3.62(m,0.6H),3.60(s,1H),3.51(s,2H),3.43–3.38(m,0.4H),3.15–3.06(m,0.4H ),2.99–2.90(m,1H),2.64–2.54(m,0.6H),2.45–2.38(m,1H),2.08–1.93(m,1H),1.23(s,1H).
[0330] Example 8
[0331] The synthesis of compound 7 was as follows Fig.21 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-isopropoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0332] Following the general procedure for coupling boronic acid ester intermediates with aryl bromides, compound 7 (10.6 mg, 9.4%) was obtained as a white solid from a mixture of B5 (100 mg, 0.24 mmol), (6-isopropoxypyridin-3-yl)boronic acid (52.8 mg, 0.29 mmol), PdCl2(dtdppf) (16 mg, 0.02 mmol) and K2CO3 (89 mg, 0.73 mmol) in 1,4-dioxane / H2O (10 mL / 4 mL). LC-MS: (ESI) m / z=468.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ8.99–8.89(m,1H),8.91–8.77(m,0.35H),8.73–8.57(m,1H ),8.36(s,1H),8.27–8.07(m,2H),8.05–7.90(m,1H),6.99–6.94(m,1H),5.52–5.26 (m,2H),3.66–3.62(m,0.5H),3.61–3.49(m,3H),3.45–3.37(m,0.5H),2.99–2.87( m,1H),2.47–2.39(m,3H),2.36–2.31(m,2H),2.10–1.91(m,1H),1.36–1.31(m,6H).
[0333] Example 9
[0334] The synthesis of compound 8 is as follows Fig. 22 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(dimethylamino)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0335] Following the general procedure for coupling boronate intermediates with aryl bromides, to a mixture of B5 (300 mg, 0.73 mmol) and G2 (181 mg, 0.73 mmol) in dioxane / H2O (10 mL / 2 mL) were added Pd(dtbpf)Cl2 (53 mg, 0.073 mmol) and K2CO3 (302 mg, 2.19 mmol) to give compound 8 (321 mg, 97%). 1H NMR(400MHz,MeOD)δ8.88–8.75(m,1H),8.53(dd,J=41.6,2.4Hz,1H),8.37(s,1H),8.12(t,J=8.9Hz ,1H),8.02–7.87(m,2H),6.83(dd,J=19.9,9.0Hz,1H),5.43(dd,J=26.8,8.8Hz,1H),3.89–3.74(m,1 H),3.67(s,1H),3.59(s,2H),3.44(d,J=29.6Hz,1H),3.17(d,J=4.9Hz,6H),3.10(d,J=15.9Hz,1H) ,2.75–2.50(m,2H),2.43(d,J=18.8Hz,3H),2.08(d,J=13.5Hz,1H).LC-MS:(ESI)m / z=452,453[M+H] +
[0336] Example 10
[0337] The synthesis of compound 9 is as follows Fig.23 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-(deuterated methyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0338] Following the general procedure for coupling boronic acid ester intermediates with aryl bromides, compound 9 (10 mg, 9.36%) was obtained as a white solid from a mixture of B5' (100 mg, 0.24 mmol), (6-methoxypyridin-3-yl)boronic acid (44 mg, 0.29 mmol), PdCl2(dtdppf) (31.8 mg, 0.02 mmol) and K2CO3 (200 mg, 1.46 mmol) in 1,4-dioxane / H2O (100 mL / 40 mL). LC-MS: (ESI) m / z=443.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ8.99–8.89(m,1H),8.80(s,0.3H),8.74–8.61(m,1H),8.38(s ,0.7H),8.22–8.09(m,2H),8.02-7.90(m,1H),7.07-6.94(m,1H),3.97–3.90(m,3H), 3.71–3.59(m,1H),3.44–3.38(m,0.6H),3.15–3.06(m,0.4H),3.0–2.86(m,1H),2.78 –2.54(m,1H),2.47-2.45(m,1H),2.45-2.40(m,1H),2.35(s,2H),2.09–1.92(m,1H).
[0339] Embodiment 11
[0340] The synthesis of compound 10 was as follows Fig.24 Shown: Synthesis of (R / S)-8-(6-cyclopropyloxypyridin-3-yl)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0341] Following the general procedure for coupling boronate intermediates with aryl bromides, compound 10 (10 mg, 4.42%) was obtained as a white solid from a mixture of B5 (200 mg, 0.47 mmol), E3 (152 mg, 0.58 mmol), PdCl2(dtdppf) (32 mg, 0.02 mmol) and K2CO3 (130 mg, 1.2 mmol) in 1,4-dioxane / H2O (10 mL / 4 mL). LC-MS: (ESI) m / z=466.2 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ8.99–8.90(m,1H),8.93–8.77(m,0.35H),8.76–8.62(m,1H),8.45–8.33 (m,1.3H),8.29–8.10(m,2H),8.05–7.91(m,1H),7.15–6.93(m,1H),5.57–5.23(m,1H),4.36-4.2 2(m,1H),3.70–3.56(m,2H),3.52(s,2H),3.14–3.06(m,0.5H),2.97-2.89(m,1H),2.72–2.54(m, 0.5H),2.47-2.41(m,2H),2.35(s,2H),2.09–1.92(m,1H),0.95–0.77(m,2H),0.74–0.66(m,2H).
[0342] Example 12
[0343] The synthesis of compound 11 is as follows Fig.25 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0344] Following the general procedure for coupling boronate intermediates with aryl bromides, to a mixture of H2 (359 mg, 1.18 mmol) and B5 (335 mg, 0.815 mmol) in dioxane / H2O (10 mL / 2 mL) was added K2CO3 (337 mg, 2.445 mmol) to give compound 11 (160 mg, 38.7%). 1H NMR(400MHz,MeOD)δ8.81(dd,J=18.5,3.4Hz,1H),8.44(dd,J=35.7,33.3Hz,2H),8.18–8.07(m,1H), 8.02–7.83(m,2H),6.67–6.53(m,1H),5.41(dd,J=25.5,11.6Hz,1H),4.20(t,J=7.1Hz,2H),4.01–3.7 3(m,3H),3.62(dd,J=31.4,2.3Hz,3H),3.42–3.33(m,2H),3.09(d,J=11.9Hz,1H),2.63(dd,J=28.2, 12.3Hz, 1H), 2.53–2.36 (m, 4H), 2.27 (s, 6H), 2.08 (d, J=13.7Hz, 1H). LC-MS: (ESI) m / z=507,508[M+H] +
[0345] Embodiment 13
[0346] The synthesis of compound 12 is as follows Fig.26 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-8-(6-(deuterated methoxy)pyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0347] Following the general procedure for coupling boronate intermediates with aryl bromides, compound 12 (10 mg, 3.2%) was obtained as a white solid from a mixture of F3 (200 mg, 0.84 mmol), B5 (287 mg, 0.70 mmol), PdCl2(dtdppf) (31 mg, 4.87 mmol) and K2CO3 (347 mg, 2.52 mmol) in 1,4-dioxane / H2O (10 mL / 4 mL). LC-MS: (ESI) m / z=443.0 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ8.98–8.94(m,1H),8.70–8.54(s,0.41H),8.33–8.25(m,1H),8.23( s,0.56H),8.14–8.06(m,1H),7.97–7.85(m,2H),6.64–6.52(m,1H),5.50–5.22(m,1H),3.6 6–3.62(m,1H),3.59(s,1H),3.51(s,2H),3.16–3.06(m,0.54H),2.99–2.88(m,1H),2.88–2 .55(m,1.5H),2.46(s,1H),2.44–2.38(m,1H),2.35(s,2H),2.09–1.93(m,1H),1.38(s,1H).
[0348] Embodiment 14
[0349] The synthesis of compound 13 is as follows Fig. 27 Shown: Synthesis of (R / S)-1-(3,3-difluoro-1-methylpiperidin-4-yl)-3-methyl-8-(6-((1R,5R / 1S,5S)-(2-methyl-2,6-diazabicyclo[3.2.0]heptane-6-yl)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
[0350] Following the general method for coupling boronate intermediates with aryl bromides, a mixture of I6 (15 mg, 0.038 mmol), B5 (12 mg, 0.058 mmol), PdCl2(dppf) (3 mg, 0.0038 mmol), Na2CO3 (6 mg, 0.12 mmol) in 1,4-dioxane / H2O (3 mL / 0.5 mL) was degassed twice with N2 and then heated to 100°C for 3 hours. The mixture was poured into a mixture of DCM (15 mL) and H2O (15 mL), and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column (DCM:MeOH=30:1) to give compound 13 (2.8 mg, 47.1%) as a white solid. 1 H NMR (400 MHz, DMSO)δ 1H NMR(400MHz,MeOD)δ8.80(d,J=18.3Hz,1H),8.46(m,J=32.8,2.4Hz,1H),8.34(s,1H),8.18–7.82(m,3H),6.56(d,J=18.0,8 .8Hz,1H),5.40(d,J=26.0,10.4Hz,1H),4.97(t,J=4.8Hz,1H),4.16–4.00(m,2H),3.90–3.70(m,2H),3.62(d,J=31.2Hz,3H ),3.43–3.34(m,1H),3.15–3.03(m,2H),2.89(d,J=10.8,4.8Hz,1H),2.64(d,J=28.0,12.4Hz,1H),2.51(s,1H),2.48(s,3H ),2.43(d,J=10.8Hz,3H),2.16(d,J=12.8,3.2Hz,1H),2.11–2.00(m,1H),1.98–1.85(m,1H).LC-MS: (ESI)m / z=520.6[M+H] +
[0351] Embodiment 14
[0352] Following the general procedure for chiral separation of racemic product 1-13, the following enantiopure products 14-41 were obtained:
[0353]
[0354]
[0355]
[0356]
[0357]
[0358] Example 12. Biological Data
[0359] Phosphorylation of ATM protein using MCF-7 cells was detected using ODYSSEY CLx (LI-COR); approximately 25 μl of cells were seeded in each blank 384-well plate, and after 24 hours, proportionally diluted compounds and etoposide were added using a stirring head and incubated at 37°C for 1 hour, and then the cells were fixed by adding 25 μl of 8% paraformaldehyde for 20 minutes at room temperature. The cells were permeabilized with 1X PBS containing 0.1% Triton X-100, blocked with 50 μl of Odyssey blocking buffer, and shaken at room temperature for 1.5 hours. The blocking buffer was removed, 20 μl of anti-pKAP1 antibody was added, and the anti-pKAP1 antibody was incubated overnight at 4 degrees on a gentle shaker. Add 20 μl of secondary antibody (IRDye800CW goat anti-rabbit IgG) solution containing DNA stain DRAQ5 (1 / 4,000), diluted (1 / 5000) in blocking buffer containing 0.1% Tween-20 to each well, and incubate with secondary antibody for 1 hour. Wash and remove solution. Immediately scan the plate using ODYSSEY CLx (LI-COR) to inhibit phosphorylation of ATM protein.
[0360] In cell-based inhibition of ATM phosphorylation, the compounds of the present invention effectively inhibit pATM signaling on MCF-7 and thus have the potential to overcome resistance to radiotherapy or chemotherapy through DNA damage repair via ATM protein.
[0361] Table 1: pATM inhibition in MCF-7 cells (IC50 units are nM)
[0362] Compound 1-41 Compound X IC50 <100 <1
[0363] Blood-brain barrier penetration:
[0364] In order to determine whether the compound can cross the blood-brain barrier (BBB), the test compound is administered to rats or mice. Four hours after administration, the rats or mice are killed, blood and brain tissue are collected, and the concentration of the test compound is analyzed. Brain penetration is defined as the ratio of the concentration of the compound in brain tissue to the concentration in plasma. P-glycoprotein and BCRP (breast cancer resistance protein) are blood-brain barrier efflux proteins, and P-glycoprotein substrates (efflux ratio>1.5) and / or BCRP substrates (efflux ratio>1.5) are outside the brain.
[0365] Table 2: Blood-brain barrier penetration
[0366]
[0367] In the brain penetration test, the ratio of the compound concentration in brain tissue to the concentration in plasma of the compounds of the present invention (Compounds 1-41) is greater than 30%, and they are not P-glycoprotein substrates and BCRP substrates, and have crossed the blood-brain barrier. Therefore, they have the potential to reach effective plasma concentrations in the brain and are used for the treatment and / or prevention of cancer brain metastases, meningeal metastases, gliomas, glioblastomas, DIPG and other central nervous system diseases.
[0368] Aldehyde Oxidase Sensitivity:
[0369] Human aldehyde oxidase (hAOX) is a cytosolic drug metabolizing enzyme expressed in human liver, similar to CYP, contributing to the oxidation of a significant amount of quinoline derivatives, but acting in the absence of NADPH cofactor. Drugs that are substrates of AOX generally exhibit high metabolic clearance rates, resulting in low exposure, and therefore reduced drug efficacy in humans (Lepri et al., PNAS, 2017, pp. E3178-E3187). The compounds of the present invention (compounds 1-41) are not substrates of human aldehyde oxidase with a long half-life, so they have the potential to achieve effective drug efficacy in the brain with a low metabolic clearance rate, for the treatment and / or prevention of cancer brain metastases, meningeal metastases, gliomas, glioblastomas, DIPG and other central nervous system diseases.
[0370] Table 3: Aldehyde oxidase sensitivity
[0371]
[0372] Although the invention describes many embodiments, our basic embodiments can be modified to provide other embodiments utilizing the compounds and methods of the invention. Therefore, the scope of the invention is defined by the appended claims rather than by the specific embodiments shown by way of example.
[0373] All references cited in this application (including but not limited to abstracts, articles, journals, publications, textbooks, papers, technical data sheets, Internet websites, databases, patents, patent applications and patent publications) are expressly incorporated herein by reference in their entirety. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art.
Claims
1. A compound comprising a structure of formula (I), wherein the compound is (I) wherein R1 is independently selected from OC1-3 alkyl, OC3-5 cycloalkyl, OC1-C3 deuterated alkyl, dimethylamine, N,N-dimethylazetidine-3-amine or 2-methyl-2,6-diazabicyclo[3.2.0]heptane; R2 is independently selected from hydrogen or fluorine; R3 is independently selected from methyl or deuterated methyl; R4 is independently selected from C1-C3 alkyl or C1-C3 deuterated alkyl.
2. The compound according to claim 1, characterized in that R1 is independently selected from methoxy, ethoxy, isopropoxy, cyclopropyloxy, deuterated methoxy, dimethylamine, N,N-dimethylazetidin-3-amine or 2-methyl-2,6-diazabicyclo[3.2.0]heptane; R2 is independently selected from hydrogen or fluorine; R3 is independently selected from methyl or deuterated methyl; R4 is independently selected from methyl, ethyl, isopropyl or deuterated methyl.
3. A pharmaceutical composition comprising the compound according to claim 1 or 2, a salt thereof, and a pharmaceutically acceptable auxiliary ingredient.
4. Use of the compound according to claim 1 or 2, or the pharmaceutical composition according to claim 3, in the preparation of a medicament for treating or preventing ATM protein activation mediated by ATM.
5. The use according to claim 4, characterized in that The protein is ataxia-telangiectasia mutated kinase.
6. The use according to claim 4, characterized in that The use of the medicament is for cancer, wherein the compound is administered simultaneously, separately or sequentially with radiation therapy.
7. The use according to claim 6, wherein the compound is administered simultaneously, separately or sequentially with at least one additional anti-tumor substance that may cause DNA breakage, the additional anti-tumor substance being selected from cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, bleomycin, olaparib, rucaparib, niraparib, tazoparib, pamiparib, pembrolizumab, nivolumab, cemiplimab, spartalizumab, sintilimab, tislelizumab, dotalizumab, atezolizumab, avelumab, durvalumab, AZD1775, VX-970, BAY1895344 and AZD6738.
8. The use according to claim 6, characterized in that The cancers are glioblastoma, diffuse intrinsic pontine glioma, astrocytoma, oligodendroglioma, ependymoma, meningioma, pituitary adenoma, vestibular schwannoma and medulloblastoma.
